

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

# **BMJ Open**

# Safety and Efficacy of Mycophenolate Mofetil in Treating NMOSD : a protocol for systematic review and metaanalysis.

	I
Journal:	BMJ Open
Manuscript ID	bmjopen-2020-040371
Article Type:	Protocol
Date Submitted by the Author:	12-May-2020
Complete List of Authors:	han, mengyu; Beijing University of Chinese Medicine; China-Japan Friendship Hospital, Ophthalmology Nong, Luqi; Beijing University of Chinese Medicine, Graduate School ; China-Japan Friendship Hospital, Ophthalmology Liu, Ziqiang; Beijing University of Chinese Medicine, Graduate School ; China-Japan Friendship Hospital, Ophthalmology Chen, You; China-Japan Friendship Hospital Chen, Yang; Beijing University of Chinese Medicine Meng, Huan; Beijing University of Chinese Medicine, Graduate School; China-Japan Friendship Hospital, Ophthalmology Qin, Yali; Sun Yat-Sen University Zhongshan Ophthalmic Center Wang, Zhijun; China-Japan Friendship Hospital, ophthalmology department Jin, Ming; China-Japan Friendship Hospital, Ophthalmology
Keywords:	OPHTHALMOLOGY, NEUROLOGY, IMMUNOLOGY





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

review only

Safety and Efficacy of Mycophenolate Mofetil in Treating NMOSD : a protocol for systematic review and meta-analysis.

Mengyu Han, PhD<sup>a,b</sup>, Luqi Nong, MD<sup>a,b</sup>, Ziqiang Liu, MD<sup>a,b</sup>, You Chen<sup>b</sup>, Yang Chen, MD<sup>a,b</sup>, Huan Meng, MD<sup>a,b</sup>, Yali Qin, MD<sup>c</sup>, Zhi-Jun Wang, MD<sup>b</sup>, Ming Jin MD<sup>b</sup>\*

<sup>a</sup>Beijing University of Chinese Medicine, Beijing 100029, China; <sup>b</sup>Department of Ophthalmology, China-Japan Friendship Hospital, Beijing 100029, China. <sup>c</sup> Sun Yat-Sen University Zhongshan Ophthalmic Center.

This study was funded by the National Natural Science Foundation of China (No. 81574029).

The funders had no role in the design, execution, or writing of the study.

The authors have no conflicts of interest to disclose.

\* Correspondence: Ming Jin, Department of Ophthalmology, China-Japan Friendship Hospital, No. 2, Yinghua Donglu, Chaoyang District, Beijing 100029, China (e-mail: jinmingyk@163.com).

# Abstract

 **Introduction** Neuromyelitis optica spectrum disorders (NMOSD) is an inflammatory and heterogeneous astrocyte disorder of the central nervous system (CNS) with the characteristic of higher incidence in women and Asian. Most patients with NMOSD have a course of recurrence and remission, which are prone to cause paralysis and blindness. A number of studies have confirmed the efficacy and promising prospect of mycophenolate mofetil (MMF) in the treatment of NMOSD. However, there are controversial about its therapeutic effect and safety. The purpose of this study is to conduct a systematic review and meta-analysis to assess the efficacy and safety of MMF in treating NMOSD.

**Methods and analysis** This systematic review will include all comparative researches, from randomized controlled trials (RCTs) to cohort studies, and case-control study. A relevant literature search will be conducted in PubMed, Web of Science, EMBASE, the Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang

Database, China Science and Technology Journal database (VIP) and CBM. We will also search registers of clinical trials, potential gray literature, and conference abstracts. There are no limits on language and publication status. The reporting quality and risk of bias will be assessed by two researchers independently. Expanded disability status scales (EDSS), annualized relapse rate (ARR)will be evaluated as the primary outcome. The secondary outcomes will include the frequency and extent of adverse events (AEs), best-corrected visual acuity (BCVA), relapse-free rate and time to the next attack. Meta-analysis will be performed using RevMan5.3 software provided by the Cochrane Collaboration and Stata 12.0.

**Ethics and dissemination** Because the data used for this systematic review will be exclusively extracted from published studies, ethical approval and informed consent of patients will not be required. The systematic review will be published in a peer-reviewed journal, presented at conferences and will be shared on social media platforms. **PROSPERO registration number:** PROSPERO CRD42020164179.

# Strengths and limitations of this study:

► This study is the first to conduct an exhaustive literature search to identify studies aimed to assess the effectiveness and safety of MMF in treating NMOSD.

► One limitation of this study is that differences in patients, interventions and primary outcomes may mean that meta-analysis cannot be conducted, and narrative and meta-analytical syntheses are planned.

► Although we will include studies published in any language, translation difficulties may arise, which will result in the exclusion of these studies.

► The analysis of different sources of heterogeneity and the assessment of risk of bias of the included studies is a key point for extracting and synthesising evidence-based conclusions.

**Keywords:** mycophenolate mofetil, neuromyelitis optica spectrum disorders, protocol, systematic review, meta-analysis.

#### 1. Introduction

Neuromyelitis optica (NMO), also known as Devic disease, is currently considered to be a rare autoimmune astrocyte disease of the central nervous system mediated by autoantibodies, dominated by humoral immunity and involving multiple immune cells and factors, with optic neuritis(ON) and acute transverse myelitis as typical clinical manifestations.<sup>1</sup> NMO has been recognized as a subtype of multiple sclerosis (MS) for more than 100 years since it was first described and reported.<sup>2</sup> Until 2004, the discovery and confirmation of anti-aquaporin-4 immunoglobulin G (AQP4-IgG) made significant progress in pathogenesis, diagnosis and treatment of NMO.<sup>3 4</sup> The concept of neuromyelitis optica spectrum disorders (NMOSD) was first proposed based on the widespread clinical use of specific AQP4-IgG,<sup>4</sup> which mainly referred to the limited NMO of positive AQP4-IgG. However, with the gradual improvement of the specificity of AQP4-IgG clinical testing, the shortcomings of the diagnostic criteria of NMO in 2006 and NMOSD in 2007 became prominent. In 2015, the international NMO diagnostic team proposed a new international diagnostic standard for NMOSD.<sup>5</sup> NMOSD includes NMO, ON, longitudinally extensive transverse myelitis and other typical demyelinating brain syndrome.<sup>5</sup> Up to now, there is no solid data on the incidence and prevalence of NMOSD in the world. According to the existing epidemiological data of small samples, middle-aged and young women are the high incidence of this disease, with the onset age ranging from 32 to 41 years old, and the incidence of female is about 10 times that of male.<sup>5</sup> The incidence and prevalence vary from region to region, with the incidence and prevalence being about 0.05-0.40 and 0.52-4.40/100,000, respectively.<sup>6</sup> The areas with a large Asian population are the region with high incidence of NMOSD.<sup>7-9</sup> Most patients with NMOSD have a course of recurrence and remission, including ON, myelitis and lesions in special parts of the brain, which are prone to cause paralysis and blindness.<sup>5</sup> NMOSD has become one of the most common causes of non-traumatic disability and blindness in young and middle-aged people, bringing heavy burdens on the life, work and study of patients, as well as the society and economy of various countries.<sup>10</sup> Relevant clinical data show that after an average of 5 years of NMO, about 1/4 of the patients will be unable to walk independently, about 10% will be wheelchair-dependent, and more than half of the patients will develop severe visual impairment in at least one eye.<sup>11</sup> In particular, ON associated with NMO (NMO-ON) has poor recovery of visual impairment even after

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

#### **BMJ** Open

conventional treatment. They often develop into severe bilateral visual impairment in the long term, leaving behind varying degrees of optic atrophy, which is different from MS.<sup>12 13</sup>

Currently, there are no uniform guidelines for the clinical management of NMOSD. The class of drugs in treating NMOSD is collectively referred to as disease modifying drugs,<sup>14</sup> and the treatment is divided into two stages: acute phase and remission phase. The former is based on corticosteroids to reduce the severity of acute attacks. Treatment options include intravenous corticosteroids (IVCSs), plasma exchange (PLEX) and immunoglobulin. Immunosuppressive agents are often used in the latter to prevent recurrence and reduce the progression of neurological disability.<sup>15</sup> Common drugs include mycophenolate mofetil (MMF), azathioprine (AZA), tacrolimus, cyclosporine, and monoclonal antibodies, etc.<sup>15</sup> Although AZA and rituximab are suggested as firstline treatments based on observational studies and expert opinion from the published guidelines for NMOSD recommending,<sup>16</sup> there are still AEs such as disease recurrence and myelosuppression, which lead to drug withdrawal in patients with MMF.<sup>17</sup> In recent years, rituximab has also been reports of infusion reactions, infection, and even death,<sup>18-</sup> <sup>20</sup> and its clinical application has been limited by factors such as high price.<sup>18</sup> <sup>21</sup> Therefore, we urgently need to find new immunoregulatory drugs for the treatment of NMOSD. The application of MMF in NMOSD is still in the exploration stage and is recommended as second-line treatments,<sup>16</sup> but a number of studies have confirmed the efficacy and promising prospect of MMF in the treatment of NMOSD,<sup>21-24</sup> and only a few adverse events (AEs) have been reported.<sup>21 22</sup> Further studies also suggested that MMF was more effective and caused fewer AEs than AZA.<sup>25 26</sup>

Although MMF is increasingly used in NMOSD, its therapeutic effect and safety are still controversial. There are no systematic reviews and meta-analysis yet that evaluated the effects of MMF against other therapies in patients with NMOSD. It is therefore timely to perform a systematic review and meta-analysis to assess the efficacy and safety of MMF on current research for its potential use in clinical practice in treating NMOSD.

#### 2. Methods

This protocol has been registered on PROSPERO (registration number: CRD 42020164179). Our protocol will follow the Meta-analysis of Observational Studies in Epidemiology (MOOSE),<sup>27</sup> the Cochrane Handbook for Systematic Reviews of Interventions and the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocol (PRISMA-P) statement guidelines. <sup>28 29</sup>

#### 2.1 Inclusion criteria for study selection

#### 2.1.1 Types of studies

 All comparative researches, from randomized controlled trials (RCTs) to cohort studies, and case-control study, covering at least two interventions, will be included. The current clinical trial results will be objectively integrated, which is conducive to the evaluation of the efficacy and safety of MMF for NMOSD. We will exclude reviews, qualitative studies, animal trials, laboratory studies and studies only involving one intervention.

#### 2.1.2 Types of patients

Patients diagnosed as having NMOSD will be included in the study.<sup>5 30</sup> There will be no restrictions based on other conditions, such as age at onset, sex, ethnicity, educational or economic status, number of relapses prior to treatment, previous treatment, duration of illness, disease severity, and baseline expanded disability status scales (EDSS), AQP4-IgG serological status.

#### 2.1.3 Types of interventions

Trials comparing MMF to placebo or to any other active drugs will be considered. Besides, the types, dosage, and frequency of MMF were not limited. Studies that MMF with combination therapy fail to objectively evaluate the efficacy and safety of MMF will be excluded. The control interventions will include AZA, tacrolimus, cyclosporine, and monoclonal antibody drugs, placebo, etc.

#### 2.1.4 Types of outcome measures

#### 2.1.4.1 Primary outcomes

 EDSS: Disability progression was defined as an increase of at least 1 point above the pre-treatment score if baseline score < 5.5, and of at least a half point if baseline score > 5.5, of the Kurtzke EDSS. Outcome measured was the mean change in the EDSS from before and after MMF treatment.<sup>31 32</sup>

#### **BMJ** Open

(2) Annualized relapse rate (ARR): A relapse is defined as neurologic symptoms lasting for > 24 h, which occur at least 30 days after the onset of a preceding event. ARR is computed as a function of the number of relapse over the number of days (years) in observation. Post-treatment ARR were compared to pre-treatment ARR.

# 2.1.4.2 Secondary outcomes

- (1) The frequency and extent of Adverse events (AEs): Any symptomatic events which had a possible, probable or definite causal relationship with MMF treatment were defined as AEs during the treatment and follow-up periods.
- (2) Relapse-free rate: the absence of relapse during the observation period of the study reported as percentage per study.<sup>32</sup>
- (3) Best-corrected visual acuity (BCVA): measured according to a validated measure such as the ETDRS chart, Snellen chart or a similar tool, other measures of visual acuity would be considered if outcomes could be justified and validated in relation to accepted relevant standard measures. Outcome measured was the mean change in the BCVA from before and after MMF treatment.<sup>34</sup>
- (4) Time to the next attack.
- (5) Relapse-free rates.

# 2.1.4.3 Security index

The safety was assessed by the occurrence of AEs. Any unexpected events that occurred during the studies will be recorded on an adverse event report form, including: <sup>35</sup>

- (1) General physical examination (temperature, pulse, respiration, blood pressure).
- (2) Routine examination of blood, urine and stool.
- (3) Liver and kidney function examination.
- (4) Gastrointestinal discomfort.
- (5) Hair loss or Alopecia.
- (6) Allergic or Anaphylactoid reactions.
- (7) Drug discontinued due to drug-related AEs.
- (8) Possible AEs and related detection indicators.
- 2.2 Search methods for the identification of studies

# 2.2.1 Electronic searches

 A relevant literature search by sensitive search strategies was conducted using the the following electronic databases from their inception to December 31, 2019: PubMed, Web of Science, EMBASE, the Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang Database, China Science and Technology Journal database (VIP) and CBM. Search methods of MeSH terms with free words were applied in English databases. The related terms are as follows: Participants (neuromyelitis optica, neuromyelitis optica spectrum disorders, Devic Neuromyelitis Optica, Devic's Neuromyelitis Optica, Devic's Syndrome, NMO spectrum disorders), Intervention (mycophenolic acid, mycophenolate mofetil, "mofetil, mycophenolate", cellcept, myfortic, RS61443). The search strategy for PubMed is listed in Table 1, which including all search terms, and other searches will be conducted based on these results. This will be appropriately adapted for search in the other databases. There are no limits on language and publication status.

# 2.2.2 Searching other resources

we will also search PROSPERO, the International Clinical Trials Registry Platform (ICTRP), ClinicalTrials.gov, dissertations, and gray literature to identify systematic reviews or clinical trials related to mycophenolate mofetil and neuromyelitis optica spectrum disorders. Relevant journals and conference processes will be manual searched. We will also review papers and bibliographies included in the trials.

# 2.3 Data collection and analysis

# 2.3.1 Selection of studies

Two reviewers (MYH and ZQL) will independently browse the titles and abstracts of all of the retrieved records to distinguish and exclude any obviously irrelevant articles. Studies only related to human subjects will be included. Any disagreements will be resolved by discussion between the 2 authors and an arbiter (MJ). The study selection procedure is presented in a PRISMA flow chart (Fig. 1).

# 2.3.2 Data extraction and management

Based on the inclusion criteria, a standard data collection form will be produced prior to data extraction. Search results will be entered into an EndNote X9 database and Page 9 of 22

#### **BMJ** Open

duplicate entries removed. Two authors (MYH and ZQL) will extract the data of interest from the eligible study and enter the following information in the data extraction sheet: The basic characteristics of each study (study design or methods, author, title, source/journal, time of publication, country, hospital setting); participants characteristics (average age, gender, sample size, inclusion and exclusion criteria, baseline situation); Interventions (type, duration, frequency and dosage of MMF, randomization, allocation concealment, blinding methods); Comparators (AZA, tacrolimus, cyclosporine, monoclonal antibodies, and placebo, etc); Outcomes (measures, main outcomes, security indexes, and follow up); If funded, it will also be recorded. When the consensus on data extraction is not available through discussion, the third reviewer (MJ) will make a decision.

# 2.3.3 Assessment of risk of bias

Two authors (Yang Chen and LQN) will independently evaluate the risk and bias using the Cochrane risk of bias (ROB) assessment tool for RCTs.<sup>36</sup> Methodological quality assessment of the included observational studies will be performed using the Newcastle–Ottawa Scale (NOS).<sup>37</sup> The RevMan software program (V.5.3) will record the selected details of each study.<sup>38</sup>

# 2.3.4 Measures of treatment effect

The risk ratio (RR) and 95% confidence interval (CI) will be used to analyze dichotomous data and measure the treatment effect. A weighted mean difference (WMD) or a standard mean difference (SMD) with 95% CIs will be used to analyze continuous outcomes.

# 2.3.5 Unit of analysis issue

We will only extract the 1st experimental period data of crossover trials to avoid carryover effects. Meanwhile, considering that there are multiple intervention groups in trials, we will combine all analogous groups into a single pairwise comparison to prevent a unit of analysis issue.

# 2.3.6 Management of missing data

Reviewer (YLQ) will contact the appropriate author of the included trials for clarification or more details via email and telephone if necessary. The missing data will

be deleted, if there is no response from the author. In this case, this will be addressed in the discussion. Qualitative analysis would be used if relevant data was not available.

# 2.3.7 Assessment of heterogeneity and data synthesis

We will use the complete case data as the analysis data. Heterogeneity will be tested with a standard Chisquare test.<sup>39</sup> In order to quantify the impact of the statistical heterogeneity on the systematic review, the I<sup>2</sup> value will be applied to calculate and present the heterogeneity degree. When P>0.1, I<sup>2</sup><50%, it is considered that there is no heterogeneity between the trials, and the fixed effect model will be used, otherwise, the random effect model will be adopted. All statistical analyses will be performed using RevMan5.3 software provided by the Cochrane Collaboration. Using the software to obtain forest plots and test the heterogeneity between the included studies. The Grades of Recommendation, Assessment, Development and Evaluation (GRADE) will be use to assess the meta-analysis findings and determine the quality of evidence. Narrative comprehensive synthesis will be adopted, if meta-analysis is not possible due to lack of clinical studies or heterogeneity.

# 2.3.8 Assessment of reporting biases

When 10 or more studies are included in a meta-analysis, we will assess funnel plot asymmetry for reporting biases and small study effects using Egger's method.<sup>40</sup> For Egger's test, P value of greater than 0.05 was determined as no considerable publication bias or small-study effects in studies. As funnel plot asymmetry does not necessarily suggest reporting bias, we will try to distinguish possible reasons for the asymmetry, including poor methodological quality and true heterogeneity of studies.

# 2.3.9 Subgroup analysis

When heterogeneity is detected, a subgroup analysis will be conducted to judge the source of heterogeneity. The criteria for a subgroup analysis are as follows:

- (1) Age.
- (2) Type of MMF.
- (3) Research type.
- (4) Participation population.
- (5) Type of control interventions.

(6) Intervention dosage, frequency and duration.

(7) AQP4-IgG serological status.

# 2.3.10 Sensitivity analysis

In the case of sufficient trials data, the ROB tool will be used to assess methodological quality. Sensitivity analysis will be performed to assess the robustness of aggregate estimates and to detect whether any single study accounts for a significant proportion of heterogeneity by removing the included studies one by one from the summary analysis. If low-quality articles are deleted, a second meta-analysis will be performed. The results and effect size of the two meta-analyses will be compared and discussed. <sup>41</sup>

**2.4 Patient and public involvement** Patients and/or the public will not participate in the study. However, once our findings are disseminated by scientific publications, they are shared through social networks, so that our conclusions can influence the behavior of neuro-ophthalmologist and health policy makers.

# Discussion

NMOSD is an inflammatory and heterogeneous astrocyte disorder of the CNS with the characteristic of higher incidence in women and Asian, concerned because of its high pathogenicity, high risk of recurrence and poor prognosis.<sup>1</sup> Most patients with NMOSD have a course of recurrence and remission, which are prone to cause paralysis and blindness,<sup>5</sup> bringing heavy burdens on the life, work and study of patients, as well as the society and economy of various countries. At present, the treatment of NMOSD is divided into two stages: acute phase (IVCSs, PLEX, and immunoglobulin) and remission phase (MMF, AZA, tacrolimus, cyclosporine, monoclonal antibodies, etc.).<sup>15</sup> AEs associated with AZA were seemingly frequent and may contribute to patient nonadherence to prescribed medication.<sup>16</sup> <sup>17</sup> In recent years, rituximab has been recommended to prevent recurrence of NMOSD, but there have also been reports of infusion reactions, infection, and even death,<sup>18-20</sup> and its clinical application has been limited by factors such as high price.<sup>18</sup> <sup>21</sup> Therefore, we urgently need to find new immunoregulatory drugs for the treatment of NMOSD.

A number of studies have confirmed the efficacy and promising prospect of MMF in the treatment of NMOSD,<sup>21-24</sup> and only a few adverse events (AEs) have been reported.

<sup>21 22</sup> Further studies also suggested that MMF was more effective and caused fewer AEs than AZA. <sup>25 26</sup> However, there are controversial about its therapeutic effect and safety. The primary objective of this systematic review is to evaluate the clinical efficacy and safety of MMF in the treatment of NMO. We will conduct qualitative and quantitative analysis of the overall data included in each study. The presented evidences were collected from RCTs and observational studies with different evidence strengths to provide more comprehensive analysis. Therefore, the heterogeneity of the methodology will be a major limitation in this systematic review, which may lead to some results not being analyzed. We expect that this systematic review will benefit patients with NMOSD, clinicians, healthcare managers and policy-makers.

# Author contributions

 MYH conceived and designed the protocol, and MYH drafted the protocol manuscript. MYH developed the search strategy, with input from ZQL and LQN. MYH and ZQL planned the data extraction. MYH, Yang Chen and ZJW planned the quality appraisal of all included studies. MYH, ZQL, LQN, Yang Chen, HM, YC, ZJW, YLQ and MJ critically revised the manuscript for methodological and intellectual content. All authors approved the final version.

Conceptualization: Meng-Yu Han, Zi-Qiang Liu, Zhi-Jun Wang, Ming Jin.

Data curation: Meng-Yu Han, Zi-Qiang Liu, Lu-Qi Nong, Huan Meng.

Formal analysis: Meng-Yu Han, Zi-Qiang Liu.

Funding acquisition: Meng-Yu Han.

Investigation: Ming Jin.

Methodology: Meng-Yu Han, Zi-Qiang Liu, Lu-Qi Nong, You Chen.

**Project administration:** Ming Jin.

Resources: Meng-Yu Han, Zi-Qiang Liu, Lu-Qi Nong, Ming Jin.

Software: Meng-Yu Han, Zi-Qiang Liu, Lu-Qi Nong.

Supervision: Meng-Yu Han, Zhi-Jun Wang, Ming Jin.

Validation: Huan Meng, Yang Chen, Ya-li Qin, Ming Jin.

Visualization: Huan Meng, Yang Chen, Ya-li Qin, Ming Jin.

Writing – original draft: Meng-Yu Han, Zi-Qiang Liu, Lu-Qi Nong, Ming Jin.

#### **BMJ** Open

Writing - review & editing: Meng-Yu Han, Zi-Qiang Liu, Lu-Qi Nong, Ming Jin.

# Reference

[1] Jasiak-Zatonska M, Kalinowska-Lyszczarz A, Michalak S, & Kozubski W. The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives. International J Molecular Sciences 2016;17(3):273.

[2] Jarius S, Wildemann B. On the contribution of Thomas Clifford Allbutt, F.R.S., to the early history of neuromyelitis optica. J Neurol 2013; 260:100-104.

[3] Yang X, Ransom R, Ma J F. The role of AQP4 in neuromyelitis optica: more answers, more questions. Neuroimmunol 2016;298:63-70.

[4] Wingerchuk D M, Lennon V A, Lucchinetti C F, et al. The spectrum of neuromyelitis optica. The Lancet Neurology 2007;6(9):805-815.

[5] Wingerchuk D M, Banwell B, Bennett J L, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85(2):177-189.

[6] Pandit L, Asgari N, Apiwattanakul M, et al. Demographic and clinical features of neuromyelitis optica: A review. Mult Scler 2015;21(7):845-853.

[7] Bukhari W, Prain KM, Waters P, et al. Incidence and Prevalence of NMOSD in Australia and New Zealand. J Neurol Neurosurg Psychiatry 2017;88(8): 632-638.
[8] Viswanathan S, WallL M. A nationwide epidemiological study on the prevalence of multiple sclerosis and neuromyelitis optica spectrum disorder with important multi-ethnic differences in Malaysia. Muh Scler 2019;25(11): 1452-1461.

[9] Miyamoto K, Fujihara K, Kira J1, eta1. Nationwide epidemiological study of neuromyelitis optician Japan. J Neurol Neurosurg Psychiatry 2018;89(6): 667-668.

[10] Wingerchuk D M, Hogancamp W F, O'Brien P C, et al. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53,1107.

[11] Jiao Y, Fryer JP, Lennon VA, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology 2013;81:1197-1204.

[12] Drori T, ChapmanJ. Diagnosis and classification of neuromyelitis optica (Devic's

syndrome). Autoimmun Rev 2014;13(4-5):531–533.

 [13] Optic Neuritis Study Group. Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial. Ophthalmology 2008;115(6): 1079-1082.

[14] Papadopoulos MC, Bennett JJ, Verkman AS. Treatment of neuromyelitis optica state-of-the-art and emerging therapies. Nat Rev Neurol 2014;10(9):493-506.

[15] Wu Y, Zhong L, Geng J.Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models. Mult Scler Relat disord 2019;27(1):412-418.

[16] Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 2014; 261(1):1-16.

[17] Elsone L, Kitley J, Luppe S, et al. Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK
[J]. Mult Scler 2014;20(11):1533-1540.

[18] Torres J, Pruitt A, Balcer L, et al. Analysis of the treatment of neuromyelitis optica.J Neurol Sci 2015;351(1-2):31-35.

[19] Annovazzi P, Capobianco M, Moiola L, et al. Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study. J Neurol 2016; 263(9):1727-1735.

[20] Collongues, N, de Seze, J. An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica. Ther Adv Neurol Disord 2016;9(3):180-188.

[21] Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 2009;66(9):1128-33.

[22] Huh S Y, Kim S H, Hyun J W, et al. Mycophenolate Mofetil in the Treatment of Neuromyelitis Optica Spectrum Disorder. JAMA Neurology 2014;71(11):1372-1378.
[23] Chen H, Zhang Y, Shi Z, et al. The Efficacy and Tolerability of Mycophenolate Mofetil in Treating Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder

#### **BMJ** Open

in Western China. Clin Neuropharmacol 2016; 39(2):81-87.

[24] Jiao Y, Cui L, Zhang W, et al. Dose effects of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorders: a case series study. BMC Neurology 2018;18(1):47.

[25] Chen H, Qiu W, Zhang Q, et al. Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder. Eur J Neurol 2017;24(1):219-226.

[26] Yang Y, Wang C J, Wang B J, et al. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder. J Neurol Sci 2018;385:192-197.

[27] Stroup DF, Berlin JA, Morton SC, et al, Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 283(15);2008-2012.

[28] Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;350:7647.

[29] Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.

[30] Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66 (10), 1485-1489.

[31] Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurol Int 1983;33 (11):1444-1452.

[32] Enriquez C A G, Espiritu A I, Pasco P M D. Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: A systematic review. Journal of Neuroimmunology 2019;332(7):126-134.

[33] Lavery AM, Verhey LH, Waldman AT. Outcome measures in relapsing-remitting multiple sclerosis: capturing disability and disease progression in clinical trials. Mult Scler Int 2014;2014, 262350.

[34] Squires H, Poku E, Bermejo I, et al. A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults. Health Technol Assess 2017;21(68):1-170.

[35] Espiritu AI, Pasco PMD. Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: A systematic review and meta-analysis. Mult Scler Relat Disord 2019;33(8):22-32.

[36] Savović J, Weeks L, Sterne JA, et al. Evaluation of the Cochrane Collaboration's tool for assessing the risk of bias in randomized trials: focus groups, online survey, proposed recommendations and their implementation. Syst Rev 2014;15:37.

[37] Wells G, Shea B, O'Connell D, et al. The Newcastle–Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Mult Scler 13(8); 968-974.

[38] Collaboration RTC. Review Manager (RevMan). 5.0. COPENHAGEN: THE NORDIC COCHRANE COLLABORATION,2008.

[39] Chen B, Benedetti A. Quantifying heterogeneity in individual participant data meta-analysis with binary outcomes. Syst Rev 2017;6:243.

[40] Egger M, Smith GD, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.

[41] Shih KC, Lun CN, Jhanji V, et al. Systematic review of randomized controlled trials in the treatment of dry eye disease in Sjogren syndrome. J Inflamm (LOND) 2017; 14:26.

07/


#### SUPPLEMENTARY MATERIAL

Table 1 Search strategy used in PubMed database.

Number	Search terms
#1	("Neuromyelitis Optica"[Mesh]) OR (((((neuromyelitis optica
	spectrum disorders [Title/Abstract]) OR Devic Neuromyelitis Optica
	[Title/Abstract]) OR Devic's Neuromyelitis Optica [Title/Abstract])
	OR Devic's Syndrome [Title/Abstract]) OR NMO spectrum disorders
	[Title/Abstract])
#2	("Mycophenolic Acid"[Mesh]) OR (((((Mycophenolate Mofetil
	[Title/Abstract]) OR "Mofetil, Mycophenolate" [Title/Abstract]) OR

	Cellcept [Title/Abstract]) OR Myfortic [Title/Abstract]) OR RS61443
	[Title/Abstract])
#3	(((("Randomized Controlled Trial" [Publication Type]) OR
	RCT[Title/Abstract])) OR (("Cohort Studies"[Mesh]) OR ((cohort
	study[Title/Abstract]) OR "studies, cohort"[Title/Abstract]))) OR
	((((Case-Referrent Studies[Title/Abstract]) OR Case-Base
	Studies[Title/Abstract])) OR (("Case-Control Studies"[Mesh]) OR
	Case-Comparison Studies[Title/Abstract]))
#4	#1 and #2 and #3

Figure1. The PRISMA flow chart of the selection process.






Figure 1. The PRISMA flow chart of the selection process.

# Reporting checklist for protocol of a systematic review.

Based on the PRISMA-P guidelines.

# Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMA-Preporting guidelines, and cite them as:

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.

			Page
		Reporting Item	Number
Title			
Identification	<u>#1a</u>	Identify the report as a protocol of a systematic review	Page 1
Update	<u>#1b</u>	If the protocol is for an update of a previous systematic	
		review, identify as such	
	For pe	eer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2 3	Registration			
4 5		<u>#2</u>	If registered, provide the name of the registry (such as	Page 2
6 7 8			PROSPERO) and registration number	
9 10 11	Authors			
12 13 14 15 16	Contact	<u>#3a</u>	Provide name, institutional affiliation, e-mail address of all	Page 1
			protocol authors; provide physical mailing address of	
17 18			corresponding author	
19 20 21 22 23	Contribution	<u>#3b</u>	Describe contributions of protocol authors and identify the	Page1,11,12
			guarantor of the review	
24 25				
26 27 28 29 30 31 32	Amendments			
		<u>#4</u>	If the protocol represents an amendment of a previously	
			completed or published protocol, identify as such and list	
33 34			changes; otherwise, state plan for documenting important	
35 36 37			protocol amendments	
38 39	Support			
39 40 41	oupport			
42 43	Sources	<u>#5a</u>	Indicate sources of financial or other support for the review	Page 1
44 45 46	Sponsor	<u>#5b</u>	Provide name for the review funder and / or sponsor	Page 1
47 48 49	Role of sponsor or	<u>#5c</u>	Describe roles of funder(s), sponsor(s), and / or	Page 1
50 51	funder		institution(s), if any, in developing the protocol	
52 53 54 55	Introduction			
56 57	Rationale	<u>#6</u>	Describe the rationale for the review in the context of what	Page 2,3,4
58 59 60		For pe	er review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2			is already known	
- 3 4	Objectives	<u>#7</u>	Provide an explicit statement of the question(s) the review	Page 5,6
5 6 7			will address with reference to participants, interventions,	
7 8 9			comparators, and outcomes (PICO)	
10 11 12 13	Methods			
14 15	Eligibility criteria	<u>#8</u>	Specify the study characteristics (such as PICO, study	Page 7,8
16 17			design, setting, time frame) and report characteristics	
18 19 20			(such as years considered, language, publication status) to	
21 22			be used as criteria for eligibility for the review	
23 24 25	Information	<u>#9</u>	Describe all intended information sources (such as	Page 7,8
25 26 27	sources		electronic databases, contact with study authors, trial	
28 29			registers or other grey literature sources) with planned	
30 31 32			dates of coverage	
33 34 35	Search strategy	<u>#10</u>	Present draft of search strategy to be used for at least one	Page 7
36 37			electronic database, including planned limits, such that it	
38 39 40 41 42			could be repeated	
	Study records -	<u>#11a</u>	Describe the mechanism(s) that will be used to manage	Page7,8
43 44 45	data management		records and data throughout the review	
46 47 48	Study records -	<u>#11b</u>	State the process that will be used for selecting studies	Page 7,8
49 50	selection process		(such as two independent reviewers) through each phase	
51 52			of the review (that is, screening, eligibility and inclusion in	
53 54 55			meta-analysis)	
56 57 58	Study records -	<u>#11c</u>	Describe planned method of extracting data from reports	Page 7,8,9
58 59 60		For pe	er review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

BMJ Open: first published as 10.1136/bmjopen-2020-040371 on 30 November 2020. Downloaded from http://bmjopen.bmj.com/ on April 23, 2024 by guest. Protected by copyright.

1	data collection		(such as piloting forms, done independently, in duplicate),	
2 3 4 5 6 7	process		any processes for obtaining and confirming data from	
			investigators	
8 9	Data items	<u>#12</u>	List and define all variables for which data will be sought	Page 8
10 11			(such as PICO items, funding sources), any pre-planned	
12 13 14			data assumptions and simplifications	
15 16 17	Outcomes and	<u>#13</u>	List and define all outcomes for which data will be sought,	Page5,6
17 18 19	prioritization		including prioritization of main and additional outcomes,	
20 21			with rationale	
22 23 24	Risk of bias in	<u>#14</u>	Describe anticipated methods for assessing risk of bias of	Page 8
25 26	individual studies		individual studies, including whether this will be done at	
27 28 29			the outcome or study level, or both; state how this	
30 31			information will be used in data synthesis	
32 33 34	Data synthesis	<u>#15a</u>	Describe criteria under which study data will be	Page 9
35 36			quantitatively synthesised	
37 38	Data synthesis	#15b	If data are appropriate for quantitative synthesis, describe	Page 9
39 40 41	Data Synthesis	<u>#100</u>	planned summary measures, methods of handling data	r age o
42 43			and methods of combining data from studies, including any	
44 45				
46 47			planned exploration of consistency (such as I2, Kendall's	
48 49			т)	
50 51 52	Data synthesis	<u>#15c</u>	Describe any proposed additional analyses (such as	Page 9,10
53 54			sensitivity or subgroup analyses, meta-regression)	
55 56 57 58	Data synthesis	<u>#15d</u>	If quantitative synthesis is not appropriate, describe the	Page 9
59 60		For pe	er review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1			type of summary planned	
2 3 4	Meta-bias(es)	<u>#16</u>	Specify any planned assessment of meta-bias(es) (such	Page 8,9
5 6 7			as publication bias across studies, selective reporting	
7 8 9			within studies)	
10 11 12	Confidence in	<u>#17</u>	Describe how the strength of the body of evidence will be	Page 9
13 14	cumulative		assessed (such as GRADE)	
15 16 17	evidence			
18 19 20	None The PRISMA	-P chec	cklist is distributed under the terms of the Creative Commons	Attribution
21 22	License CC-BY 4.0. This checklist can be completed online using https://www.goodreports.org/, a tool			
23 24	made by the EQUATOR Network in collaboration with Penelope.ai			
25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51				
51 52 53 54 55 56 57 58 59 60		For pe	er review only - http://bmjopen.bmj.com/site/about/quidelines.xhtml	
60		For pe	er review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

# **BMJ Open**

# Safety and Efficacy of Mycophenolate Mofetil in Treating NMOSD : a protocol for systematic review and metaanalysis.

Journal:	BMJ Open
Manuscript ID	bmjopen-2020-040371.R1
Article Type:	Protocol
Date Submitted by the Author:	14-Jul-2020
Complete List of Authors:	han, mengyu; Beijing University of Chinese Medicine; China-Japan Friendship Hospital, Ophthalmology Nong, Luqi; Beijing University of Chinese Medicine, Graduate School ; China-Japan Friendship Hospital, Ophthalmology Liu, Ziqiang; Beijing University of Chinese Medicine, Graduate School ; China-Japan Friendship Hospital, Ophthalmology Chen, You; China-Japan Friendship Hospital Chen, Yang; Beijing University of Chinese Medicine Meng, Huan; Beijing University of Chinese Medicine, Graduate School; China-Japan Friendship Hospital, Ophthalmology Qin, Yali; Sun Yat-Sen University Zhongshan Ophthalmic Center Wang, Zhijun; China-Japan Friendship Hospital, ophthalmology department Jin, Ming; China-Japan Friendship Hospital, Ophthalmology
<b>Primary Subject Heading</b> :	Ophthalmology
Secondary Subject Heading:	Neurology, Evidence based practice
Keywords:	OPHTHALMOLOGY, NEUROLOGY, IMMUNOLOGY, Neuro-ophthalmology < NEUROLOGY





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

reliez on

Safety and Efficacy of Mycophenolate Mofetil in Treating NMOSD : a protocol for systematic review and meta-analysis.

Mengyu Han, PhD<sup>a,b</sup>, Luqi Nong, MD<sup>a,b</sup>, Ziqiang Liu, MD<sup>a,b</sup>, You Chen<sup>b</sup>, Yang Chen, MD<sup>a,b</sup>, Huan Meng, MD<sup>a,b</sup>, Yali Qin, MD<sup>c</sup>, Zhi-Jun Wang, MD<sup>b</sup>, Ming Jin MD<sup>b</sup>\*

<sup>a</sup>Beijing University of Chinese Medicine, Beijing 100029, China; <sup>b</sup>Department of Ophthalmology, China-Japan Friendship Hospital, Beijing 100029, China. <sup>c</sup> Sun Yat-Sen University Zhongshan Ophthalmic Center.

\* Correspondence: Ming Jin, Department of Ophthalmology, China-Japan Friendship Hospital, No. 2, Yinghua Donglu, Chaoyang District, Beijing 100029, China (e-mail: jinmingyk@163.com).

#### Abstract

 **Introduction** Neuromyelitis optica spectrum disorders (NMOSD) is an inflammatory and heterogeneous astrocyte disorder of the central nervous system (CNS) with the characteristic of higher incidence in women and Asian. Most patients with NMOSD have a course of recurrence and remission that is prone to cause paralysis and blindness. Several studies have confirmed the efficacy and promising prospect of mycophenolate mofetil (MMF) in the treatment of NMOSD. Yet its therapeutic effect and safety are controversial. This research aims to perform a systematic review and meta-analysis to evaluate MMF's effectiveness and safety in treating NMOSD.

**Methods and analysis** This systematic review will cover all comparative researches, from randomized controlled trials (RCTs) to cohort studies, and case-control study. A relevant literature search will be conducted in PubMed, Web of Science, EMBASE, the Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang Database, China Science and Technology Journal database (VIP) and Chinese Biomedical Literature database (CBM). We will also search registers of clinical trials, potential gray literature, and abstracts from conferences. There are no limits on language and publication status. The reporting quality and risk of bias will be assessed by two researchers independently. Expanded disability status scales (EDSS), annualized relapse rate (ARR)will be evaluated as the primary outcome. The secondary

#### **BMJ** Open

outcomes will consist of the frequency and severity of adverse events (AEs), bestcorrected visual acuity (BCVA), relapse-free rate and time to the next attack. A metaanalysis will be performed using RevMan5.3 software provided by the Cochrane Collaboration and Stata 12.0.

**Ethics and dissemination** Because the data used for this systematic review will be exclusively extracted from published studies, ethical approval and informed consent of patients will not be required. The systematic review will be published in a peer-reviewed journal, presented at conferences and will be shared on social media platforms.

**PROSPERO registration number:** PROSPERO CRD42020164179.

# Strengths and limitations of this study:

► This study will carry out an exhaustive literature search to identify studies aimed at evaluating the efficacy and safety of MMF in treating NMOSD.

► One limitation of this study is that differences in patients, interventions and primary outcomes may mean that meta-analysis cannot be performed and there are plans for narrative and meta- analytical syntheses.

► Although we will include studies published in any language, translation difficulties may arise, which will result in the exclusion of these studies.

► The analysis of various sources of heterogeneity and the assessment of risk of bias of the included studies is a critical point for extracting and synthesizing evidence-based conclusions.

**Keywords:** mycophenolate mofetil, neuromyelitis optica spectrum disorders, protocol, systematic review, meta-analysis.

# 1. Introduction

Neuromyelitis Optica (NMO), also known as Devic disease, is generally considered to be a rare autoimmune astrocyte disorder of the central nervous system (CNS), induced by autoantibodies, dominated by humoral immunity and involving numerous immune cells and factors, with optic neuritis(ON) and acute transverse myelitis as typical clinical manifestations.<sup>1</sup> NMO has been known as a subtype of multiple sclerosis (MS) for over 100 years since it was first described and reported.<sup>2</sup> Until 2004, the discovery and confirmation of anti-aquaporin-4 immunoglobulin G (AQP4-IgG) had made substantial progress in pathogenesis, diagnosis, and treatment of NMO.<sup>34</sup> The notion of neuromyelitis optica spectrum disorders (NMOSD) was first proposed based on the wide clinical use of specific AQP4-IgG,<sup>4</sup> which mainly referred to the minimal AQP4-IgG positive NMO. However, the deficiencies of the diagnostic criteria of NMO in 2006 and NMOSD in 2007 became prominent with the incremental improvement of the specificity of clinical AQP4-IgG tests. In 2015, a groundbreaking international diagnostic protocol for NMOSD was put forward by the global NMO diagnostic team.<sup>5</sup> NMOSD consists of NMO, ON, longitudinally extensive transverse myelitis and other common cerebral demyelinating syndromes.<sup>5</sup> There are so far no reliable statistics on the worldwide incidence and prevalence of NMOSD. According to the current epidemiological evidence of small samples, the high incidence of this disease is among middle-aged and young women, with the onset age varying from 32 to 41 years old, and the incidence in females is about 10 times that of males.<sup>5</sup> The incidence and prevalence of approximately 0.05-0.40 and 0.52-4.40/100,000 vary from region to region.<sup>6</sup> A populous region of Asia is the region with a high incidence of NMOSD.<sup>7-9</sup> Most NMOSD patients have a recurrence and remission including ON, myelitis, and lesions in special parts of the brain that are vulnerable to cause paralysis and blindness.<sup>5</sup> NMOSD has become one of the most common causes of non-traumatic disability and blindness in young and middle-aged individuals, putting heavy burdens on the life, work and study, as well as the society and economy of various countries.<sup>10</sup> Clinical studies indicate that approximately 1/4 of patients will not be able to walk independently after an average of 5 years of NMO, approximately 10% will be wheelchair-dependent, and more than half of patients will have serious vision loss in at least one eye.<sup>11</sup> In particular, ON associated with NMO (NMO-ON) possesses poor recovery even after traditional therapy, which often progresses into significant bilateral visual loss in the long term, leaving behind varying degrees of optic atrophy, which is different from MS.<sup>12 13</sup>

Currently, there are no standardized guidelines for the clinical management of NMOSD. The class of NMOSD drugs is commonly referred to as disease-modifying drugs,<sup>14</sup> and the treatment is split into two stages: the acute phase and the period of remission. The Page 5 of 21

#### **BMJ** Open

former is based on corticosteroids to reduce the severity and frequency of acute attacks that include intravenous corticosteroids (IVCSs), plasma exchange (PLEX), and immunoglobulin. Immunosuppressive agents, including mycophenolate mofetil (MMF), azathioprine (AZA), cyclophosphamide, methotrexate, mitoxantrone, tacrolimus, cyclosporine, and monoclonal antibodies, are frequently used during the process of recovery to avoid recurrence and to mitigate the progression of neurological impairment.<sup>15</sup><sup>16</sup> Although AZA and rituximab are recommended as first-line therapies obtained from clinical trials and expert opinion from the published guidelines for NMOSD,<sup>16</sup> there are still adverse events (AEs) such as disease recurrence and myelosuppression that result in drug withdrawal or replacement of patients with NMOSD.<sup>17</sup> Rituximab has also been reported in recent years as infusion reactions, infection, and even death, <sup>18-20</sup> and its clinical application has been constrained by such factors as high price.<sup>18</sup><sup>21</sup> Therefore, a better immunosuppressant for the treatment of NMOSD is urgently needed. The application of MMF in NMOSD is still under investigation and is recommended as second-line treatments,<sup>16</sup> but some studies have verified MMF's efficacy and promising potential,<sup>21-24</sup> and only a few AEs were published.<sup>21 22</sup> Especially, additional studies have also indicated that MMF was more effective and triggered less AEs than AZA.<sup>25 26</sup> In patients experiencing AEs or poor response to AZA, MMF is recommended as an alternative therapy.<sup>16</sup>

Although MMF is increasingly employed in NMOSD, there is still controversy about its related harms and benefits. At present, only low evidence exists concerning comparative treatment efficacy of MMF with other drugs. Based on current clinical trials, it is therefore timely to perform a systematic review and meta-analysis to elucidate the efficacy and safety of MMF in treating NMOSD.

# 2. Methods

This protocol has been registered on PROSPERO (registration number: CRD 42020164179). Our protocol will follow the Meta-analysis of Observational Studies in Epidemiology (MOOSE),<sup>27</sup> the Cochrane Handbook for Systematic Reviews of Interventions and the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocol (PRISMA-P) statement guidelines. <sup>28 29</sup>

# 2.1 Inclusion criteria for study selection

# 2.1.1 Types of studies

All comparative researches, from randomized controlled trials (RCTs) to cohort studies, and case-control study, covering at least two interventions, will be included. The current clinical trial results will be objectively integrated, which is conducive to the evaluation of the efficacy and safety of MMF for NMOSD. We will exclude reviews, qualitative studies, animal trials, laboratory studies and studies only involving one intervention.

# 2.1.2 Types of patients

Patients diagnosed as having NMOSD will be included in this study.<sup>5 30</sup> There will be no restrictions based on other conditions, such as age at onset, sex, ethnicity, educational or economic status, number of pre-treatment relapses, previous treatment, duration of illness, disease severity, and baseline expanded disability status scales (EDSS), AQP4-IgG serological status.

# 2.1.3 Types of interventions

Trials comparing MMF to placebo or any other active substances, including AZA, cyclophosphamide, methotrexate, mitoxantrone, tacrolimus, cyclosporine, and monoclonal antibodies, will be considered. Besides, the types, dosage, and frequency of MMF were not limited. Studies that MMF with combination therapy fail to objectively evaluate the efficacy and safety of MMF will be eliminated.

# 2.1.4 Types of outcome measures

#### 2.1.4.1 Primary outcomes

- (1) EDSS: Disability progression was characterized as an increase in the Kurtzke EDSS by at least 1 point above the pre-treatment score if baseline score < 5.5, and by at least half-point if baseline score > 5.5. Outcome measured was the mean changes of EDSS before and after MMF treatment.<sup>31 32</sup>
- (2) Annualized relapse rate (ARR): Relapse is equivalent to a neurologic symptom lasting for > 24 h, which occurs at least 30 days after the onset of a preceding event. ARR is computed as the number of relapses divided by the time in years (days). Post-treatment ARR was contrasted with pre-treatment ARR. <sup>33</sup>

# 2.1.4.2 Secondary outcomes

#### **BMJ** Open

- The frequency and extent of AEs: During treatment and follow-up periods, any symptomatic events which had a possible, probable or definite causal relationship to MMF treatment were defined as AEs.
- (2) Relapse-free rate: The absence of relapse during the observation period of the study reported as percentage per study.<sup>32</sup>
- (3) Best-corrected visual acuity (BCVA): BCVA was measured using a standardized test, such as the ETDRS chart, Snellen chart or similar method, and other visual acuity measures would be allowed if findings could be justified as well as validated concerning accepted relevant standard measures. Outcome measured was the mean change of BCVA from before and after MMF treatment.<sup>34</sup>
- (4) Time to the next attack.

# 2.1.4.3 Security index

The safety was assessed by the occurrence of AEs. Any unexpected events that occurred during the studies will be recorded on an AEs report form, including: <sup>35</sup>

- (1) General physical examination (temperature, pulse, respiration, blood pressure).
- (2) Routine examination of blood, urine and stool.
- (3) Liver and kidney function examination.
- (4) Gastrointestinal discomfort.
- (5) Hair loss or Alopecia.
- (6) Allergic or Anaphylactoid reactions.
- (7) Drug discontinued due to drug-related AEs.
- (8) Possible AEs and related detection indicators.

# 2.2 Search methods for the identification of studies

# 2.2.1 Electronic searches

A relevant literature search by sensitive search strategies was conducted using the following electronic databases from their inception to June 31, 2020: PubMed, Web of Science, EMBASE, the Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang Database, China Science and Technology Journal database (VIP) and Chinese Biomedical Literature database (CBM). Search methods of MeSH terms with free words were applied in English databases. The related terms are as follows:

Participants (neuromyelitis optica, neuromyelitis optica spectrum disorders, Devic Neuromyelitis Optica, Devic's Neuromyelitis Optica, Devic's Syndrome, NMO spectrum disorders), Intervention (mycophenolic acid, mycophenolate mofetil, "mofetil, mycophenolate", cellcept, myfortic, RS61443). The search strategy for PubMed is described in Table 1, which will include all search terms, and other searches will be carried out based on those results. This will be suitably adapted to search in the other databases. There are no limits on language and publication status.

# 2.2.2 Searching other resources

 we will also search PROSPERO, the International Clinical Trials Registry Platform (ICTRP), ClinicalTrials.gov, dissertations, and gray literature to identify systematic reviews or clinical trials related to mycophenolate mofetil and neuromyelitis optica spectrum disorders. Manual searches will be conducted for related journals and conference processes. We will also review papers and bibliographies included in the trials.

# 2.3 Data collection and analysis

# 2.3.1 Selection of studies

Two reviewers (MYH and ZQL) will independently browse the titles and abstracts of all of the retrieved records to distinguish and exclude any irrelevant articles. Studies only related to human subjects are to be included. Any discord will be resolved by discussion between the two authors and an arbiter (MJ). The selection procedure for the study is shown in a PRISMA flow chart (Fig. 1).

#### 2.3.2 Data extraction and management

Based on the inclusion criteria, a standard form of data collection will be produced prior to data extraction. Search results will be entered into an EndNote X9 database and duplicate entries removed. Two authors (MYH and ZQL) will extract the data of interest from the eligible study and enter the data extraction sheet as follows: The basic characteristics of each study (study design or methods, author, title, source/journal, time of publication, country, hospital setting); participants characteristics (average age, gender, sample size, inclusion and exclusion criteria, baseline situation); Interventions (type, duration, frequency and dosage of MMF, randomization, allocation concealment,

#### **BMJ** Open

blinding methods); Comparators (AZA, tacrolimus, cyclosporine, monoclonal antibodies, and placebo, etc); Outcomes (measures, main outcomes, security indexes, and follow up); If funded, it will also be recorded. When the consensus on data extraction is not available through discussion, the third reviewer (MJ) will make a decision.

# 2.3.3 Assessment of risk of bias

Two authors (Yang Chen and LQN) will independently estimate the risk and bias using the Cochrane risk of bias (ROB) assessment tool for RCTs.<sup>36</sup> Methodological quality evaluation of the included observational studies will be carried out using the Newcastle–Ottawa Scale (NOS).<sup>37</sup> The RevMan software program (V.5.3) will document the selected details of each study.<sup>38</sup>

# 2.3.4 Measures of treatment effect

The risk ratio (RR) and 95% confidence interval (CI) will be used to analyze dichotomous data and calculate the treatment effect. A weighted mean difference (WMD) or a standard mean difference (SMD) with 95% CIs will be used to analyze continuous outcomes.

# 2.3.5 Unit of analysis issue

We will only extract the 1st experimental period data of crossover trials to avoid carryover effects. In the meantime, given that there are multiple intervention groups in trials, we will combine all analogous groups into a single pairwise comparison to avoid the issue of a unit of analysis.

#### 2.3.6 Management of missing data

Reviewer (YLQ and You Chen) will contact the appropriate author of the included trials for clarification or more details via email and telephone if necessary. The missing data will be deleted, if there is no response from the author. That will be addressed in the discussion in this case. If quantitative data were not available, then the qualitative analysis should be used.

# 2.3.7 Assessment of heterogeneity and data synthesis

We will use all of the case data for the analysis data. Heterogeneity will be tested with a standard Chisquare test.<sup>39</sup> To quantify the impact of the statistical heterogeneity on

the systematic review, the  $I^2$  value will be applied to calculate and present the heterogeneity degree. If P>0.1,  $I^2$ <50%, it is considered that there is no heterogeneity between the trials, and the model of fixed effect will be used, otherwise, the model of random effect will be adopted. All statistical analyzes will be performed using the RevMan5.3 software provided by the Cochrane Collaboration. Using the software to obtain forest plots and test the heterogeneity between the included studies. The Grades of Recommendation, Assessment, Development and Evaluation (GRADE) will be used to assess the meta-analysis findings and determine the quality of evidence. Where meta-analysis is not feasible due to lack of clinical trials or heterogeneity, systematic narrative synthesis is adopted.

# 2.3.8 Assessment of reporting biases

When 10 or more studies are included in a meta-analysis, we will evaluate funnel plot asymmetry for reporting biases and small-study effects using Egger's method.<sup>40</sup> For Egger's test, P value of greater than 0.05 was determined as no significant publishing bias or small-study effects in studies. As funnel plot asymmetry does not necessarily suggest reporting bias, we will attempt to recognize potential causes for the asymmetry, including poor methodological quality and true heterogeneity of studies.

# 2.3.9 Subgroup analysis

Upon detection of heterogeneity, a subgroup analysis will be carried out to judge the source of heterogeneity. The criteria for a subgroup analysis are as follows:

(1) Age.

- (2) Type of MMF.
- (3) Research type.
- (4) Participation population.
- (5) Type of control interventions.
- (6) Intervention dosage, frequency and duration.
- (7) AQP4-IgG serological status.

# 2.3.10 Sensitivity analysis

The ROB tool will be used to estimate methodological quality in the case of sufficient data from trials. Sensitivity analysis will be performed to determine the robustness of

#### **BMJ** Open

aggregate estimates and to detect whether any single study accounts for a substantial proportion of heterogeneity by eliminating the included studies from the summary review one by one. If low-quality articles are deleted, then a second meta-analysis will be carried out. Comparison and discussion of the results and effect size of the two meta-analyses will be held. <sup>41</sup>

**2.4 Patient and public involvement** Patients and/or the public will not participate in the study. However, once scientific publications disseminate our findings, they are circulated across social networks so that our conclusions will affect the actions of neuro-ophthalmologists and health policymakers.

#### Discussion

Pathogenesis, diagnosis and treatment of NMO are rapidly growing areas of research as AQP4-IgG were first identified. Patients with NMOSD should receive standardized and personalized immunotherapy as soon as possible, as any further acute episodes may result in severe and often irreversible disability. The challenges in discovering new and better drugs for NMO are the rareness of the disease and the unfavorable prognosis in many cases, which make clinical studies with placebo groups difficult.<sup>16</sup> Many studies have confirmed the efficacy and promising prospect of MMF in the treatment of NMOSD,<sup>21-24</sup> and only a few AEs were reported. <sup>21 22</sup> Additional studies have also indicated that MMF was more effective and triggered less AEs than AZA.<sup>25 26</sup> However, its therapeutic effect and safety remain controversial. The primary aim of this systematic review is to determine MMF's clinical effectiveness and safety in treating NMOSD. The overall data used in each analysis will be evaluated qualitatively and quantitatively. To provide a more detailed review, the evidence provided was obtained from RCTs and observational studies with different evidence strengths. Hence, the methodology's variability would be a significant weakness of this systematic analysis, which may result in certain results not being evaluated. We expect that this systematic review will benefit patients with NMOSD, physicians, health care administrators and policy-makers.

#### **Author contributions**

MYH conceived and designed the protocol, and MYH drafted the protocol manuscript. MYH developed the search strategy, with input from ZQL and LQN. MYH and ZQL planned data extraction. MYH, Yang Chen and ZJW planned the quality appraisal of all included studies. MYH, ZQL, LQN, Yang Chen, HM, You Chen, ZJW, YLQ and MJ critically revised the manuscript for methodological and intellectual content. All authors approved the final version.

Conceptualization: Meng-Yu Han, Zi-Qiang Liu, Zhi-Jun Wang, Ming Jin.

Data curation: Meng-Yu Han, Zi-Qiang Liu, Lu-Qi Nong, Huan Meng.

Formal analysis: Meng-Yu Han, Zi-Qiang Liu.

Funding acquisition: Meng-Yu Han.

Investigation: Ming Jin.

 Methodology: Meng-Yu Han, Zi-Qiang Liu, Lu-Qi Nong, You Chen.

Project administration: Ming Jin.

Resources: Meng-Yu Han, Zi-Qiang Liu, Lu-Qi Nong, Ming Jin.

Software: Meng-Yu Han, Zi-Qiang Liu, Lu-Qi Nong.

Supervision: Meng-Yu Han, Zhi-Jun Wang, Ming Jin.

Validation: Huan Meng, Yang Chen, Ya-li Qin, Ming Jin.

Visualization: Huan Meng, Yang Chen, Ya-li Qin, Ming Jin.

Writing – original draft: Meng-Yu Han, Zi-Qiang Liu, Lu-Qi Nong, Ming Jin.

Writing – review & editing: Meng-Yu Han, Zi-Qiang Liu, Lu-Qi Nong, Ming Jin.

**Funding:** This study was funded by the National Natural Science Foundation of China (No. 81574029). The funders had no role in the design, execution, or writing of the study.

Competing interests: None declared.

#### Reference

[1] Jasiak-Zatonska M, Kalinowska-Lyszczarz A, Michalak S, & Kozubski W. The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives. International J Molecular Sciences 2016;17(3):273.

#### **BMJ** Open

[2] Jarius S, Wildemann B. On the contribution of Thomas Clifford Allbutt, F.R.S., to the early history of neuromyelitis optica. J Neurol 2013; 260:100-104.

[3] Yang X, Ransom R, Ma J F. The role of AQP4 in neuromyelitis optica: more answers, more questions. Neuroimmunol 2016;298:63-70.

[4] Wingerchuk D M, Lennon V A, Lucchinetti C F, et al. The spectrum of neuromyelitis optica. The Lancet Neurology 2007;6(9):805-815.

[5] Wingerchuk D M, Banwell B, Bennett J L, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85(2):177-189.

[6] Pandit L, Asgari N, Apiwattanakul M, et al. Demographic and clinical features of neuromyelitis optica: A review. Mult Scler 2015;21(7):845-853.

[7] Bukhari W, Prain KM, Waters P, et al. Incidence and Prevalence of NMOSD in Australia and New Zealand. J Neurol Neurosurg Psychiatry 2017;88(8): 632-638.
[8] Viswanathan S, WallL M. A nationwide epidemiological study on the prevalence of multiple sclerosis and neuromyelitis optica spectrum disorder with important multi-ethnic differences in Malaysia. Muh Scler 2019;25(11): 1452-1461.

[9] Miyamoto K, Fujihara K, Kira J1, eta1. Nationwide epidemiological study of neuromyelitis optician Japan. J Neurol Neurosurg Psychiatry 2018;89(6): 667-668.

[10] Wingerchuk D M, Hogancamp W F, O'Brien P C, et al. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53,1107.

[11] Jiao Y, Fryer JP, Lennon VA, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology 2013;81:1197-1204.

[12] Drori T, ChapmanJ. Diagnosis and classification of neuromyelitis optica (Devic's syndrome). Autoimmun Rev 2014;13(4-5):531–533.

[13] Optic Neuritis Study Group. Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial. Ophthalmology 2008;115(6): 1079-1082.

[14] Papadopoulos MC, Bennett JI, Verkman AS. Treatment of neuromyelitis optica state-of-the-art and emerging therapies. Nat Rev Neurol 2014;10(9):493-506.

[15] Wu Y, Zhong L, Geng J.Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models. Mult Scler Relat disord 2019;27(1):412-418.

 [16] Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 2014; 261(1):1-16.

[17] Elsone L, Kitley J, Luppe S, et al. Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK
[J]. Mult Scler 2014;20(11):1533-1540.

[18] Torres J, Pruitt A, Balcer L, et al. Analysis of the treatment of neuromyelitis optica.J Neurol Sci 2015;351(1-2):31-35.

[19] Annovazzi P, Capobianco M, Moiola L, et al. Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study. J Neurol 2016; 263(9):1727-1735.

[20] Collongues, N, de Seze, J. An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica. Ther Adv Neurol Disord 2016;9(3):180-188.

[21] Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 2009;66(9):1128-33.

[22] Huh S Y, Kim S H, Hyun J W, et al. Mycophenolate Mofetil in the Treatment of Neuromyelitis Optica Spectrum Disorder. JAMA Neurology 2014;71(11):1372-1378.

[23] Chen H, Zhang Y, Shi Z, et al. The Efficacy and Tolerability of Mycophenolate Mofetil in Treating Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder in Western China. Clin Neuropharmacol 2016; 39(2):81-87.

[24] Jiao Y, Cui L, Zhang W, et al. Dose effects of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorders: a case series study. BMC Neurology 2018;18(1):47.

[25] Chen H, Qiu W, Zhang Q, et al. Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder. Eur J Neurol 2017;24(1):219-226.

[26] Yang Y, Wang C J, Wang B J, et al. Comparison of efficacy and tolerability of

#### **BMJ** Open

azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder. J Neurol Sci 2018;385:192-197.

[27] Stroup DF, Berlin JA, Morton SC, et al, Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 283(15);2008-2012.

[28] Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;350:7647.

[29] Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.

[30] Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66 (10), 1485-1489.

[31] Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurol Int 1983;33 (11):1444-1452.

[32] Enriquez C A G, Espiritu A I, Pasco P M D. Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: A systematic review. Journal of Neuroimmunology 2019;332(7):126-134.

[33] Lavery AM, Verhey LH, Waldman AT. Outcome measures in relapsing-remitting multiple sclerosis: capturing disability and disease progression in clinical trials. Mult Scler Int 2014;2014, 262350.

[34] Squires H, Poku E, Bermejo I, et al. A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults. Health Technol Assess 2017;21(68):1-170.

[35] Espiritu AI, Pasco PMD. Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: A systematic review and meta-analysis. Mult Scler Relat Disord 2019;33(8):22-32.

[36] Savović J, Weeks L, Sterne JA, et al. Evaluation of the Cochrane Collaboration's tool for assessing the risk of bias in randomized trials: focus groups, online survey, proposed recommendations and their implementation. Syst Rev 2014;15:37.

[37] Wells G, Shea B, O'Connell D, et al. The Newcastle–Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Mult Scler 13(8); 968-

974.

[38] Collaboration RTC. Review Manager (RevMan). 5.0. COPENHAGEN: THE NORDIC COCHRANE COLLABORATION,2008.

[39] Chen B, Benedetti A. Quantifying heterogeneity in individual participant data meta-analysis with binary outcomes. Syst Rev 2017;6:243.

[40] Egger M, Smith GD, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.

[41] Shih KC, Lun CN, Jhanji V, et al. Systematic review of randomized controlled trials in the treatment of dry eye disease in Sjogren syndrome. J Inflamm (LOND) 2017; 14:26.

Table 1 Search strategy used in PubMed database.

Number	Search terms
#1	("Neuromyelitis Optica"[Mesh]) OR (((((neuromyelitis optica
	spectrum disorders [Title/Abstract]) OR Devic Neuromyelitis Optica
	[Title/Abstract]) OR Devic's Neuromyelitis Optica [Title/Abstract])
	OR Devic's Syndrome [Title/Abstract]) OR NMO spectrum disorders
	[Title/Abstract])
#2	("Mycophenolic Acid"[Mesh]) OR (((((Mycophenolate Mofetil
	[Title/Abstract]) OR "Mofetil, Mycophenolate" [Title/Abstract]) OR
	Cellcept [Title/Abstract]) OR Myfortic [Title/Abstract]) OR RS61443
	[Title/Abstract])
#3	#1 and #2

Figure1. The PRISMA flow chart of the selection process.




Figure1. The PRISMA flow chart of the selection process.

# Reporting checklist for protocol of a systematic review.

Based on the PRISMA-P guidelines.

## Instructions to authors

 Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMA-Preporting guidelines, and cite them as:

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.

44 45				Page
46 47			Reporting Item	Number
48 49 50 51	Title			
52 53 54	Identification	<u>#1a</u>	Identify the report as a protocol of a systematic review	Page 1
55 56 57 58	Update	<u>#1b</u>	If the protocol is for an update of a previous systematic review, identify as such	
59 60		For pe	er review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2 3	Registration			
4 5		<u>#2</u>	If registered, provide the name of the registry (such as	Page 2
6 7 8			PROSPERO) and registration number	
9 10 11 12	Authors			
13 14	Contact	<u>#3a</u>	Provide name, institutional affiliation, e-mail address of all	Page 1
15 16			protocol authors; provide physical mailing address of	
17 18 19			corresponding author	
20 21	Contribution	<u>#3b</u>	Describe contributions of protocol authors and identify the	Page1,11
22 23			guarantor of the review	
24 25 26 27	Amendments			
27 28 29				
29 30 31		<u>#4</u>	If the protocol represents an amendment of a previously	
32 33			completed or published protocol, identify as such and list	
34 35			changes; otherwise, state plan for documenting important	
36 37			protocol amendments	
38 39 40	Support			
41 42 43 44	Sources	<u>#5a</u>	Indicate sources of financial or other support for the review	Page 1
44 45 46 47	Sponsor	<u>#5b</u>	Provide name for the review funder and / or sponsor	Page 1
48 49	Role of sponsor or	<u>#5c</u>	Describe roles of funder(s), sponsor(s), and / or institution(s),	Page 1
50 51 52	funder		if any, in developing the protocol	
53 54 55	Introduction			
56 57 58	Rationale	<u>#6</u>	Describe the rationale for the review in the context of what is	Page
59 60		For pee	er review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2			already known	2,3,4
3 4	Objectives	<u>#7</u>	Provide an explicit statement of the question(s) the review	Page 5,6
5 6 7			will address with reference to participants, interventions,	
7 8 9			comparators, and outcomes (PICO)	
10 11 12 13	Methods			
14 15	Eligibility criteria	<u>#8</u>	Specify the study characteristics (such as PICO, study	Page 7,8
16 17			design, setting, time frame) and report characteristics (such	
18 19 20			as years considered, language, publication status) to be	
20 21 22 23			used as criteria for eligibility for the review	
24 25	Information	<u>#9</u>	Describe all intended information sources (such as electronic	Page 7,8
26 27 28 29 30	sources		databases, contact with study authors, trial registers or other	
			grey literature sources) with planned dates of coverage	
31 32 33	Search strategy	<u>#10</u>	Present draft of search strategy to be used for at least one	Page 7
33 34 35			electronic database, including planned limits, such that it	
36 37			could be repeated	
38 39 40	Study records -	<u>#11a</u>	Describe the mechanism(s) that will be used to manage	Page7,8
41 42	data management		records and data throughout the review	
43 44				
45 46	Study records -	<u>#11b</u>	State the process that will be used for selecting studies (such	Page 7,8
47 48 40	selection process		as two independent reviewers) through each phase of the	
49 50 51			review (that is, screening, eligibility and inclusion in meta-	
52 53			analysis)	
54 55	Study records -	<u>#11c</u>	Describe planned method of extracting data from reports	Page
56 57 58	data collection		(such as piloting forms, done independently, in duplicate),	7,8,9
59 60		For pee	r review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1	process		any processes for obtaining and confirming data from	
2 3 4			investigators	
5 6 7	Data items	<u>#12</u>	List and define all variables for which data will be sought	Page 8
8 9			(such as PICO items, funding sources), any pre-planned	
10 11 12			data assumptions and simplifications	
13 14	Outcomes and	<u>#13</u>	List and define all outcomes for which data will be sought,	Page5,6
15 16 17	prioritization		including prioritization of main and additional outcomes, with	
17 18 19			rationale	
20 21 22	Risk of bias in	<u>#14</u>	Describe anticipated methods for assessing risk of bias of	Page 7,8
23 24	individual studies		individual studies, including whether this will be done at the	
25 26			outcome or study level, or both; state how this information	
27 28 29 30 31 32 33 34 35			will be used in data synthesis	
	Data synthesis	<u>#15a</u>	Describe criteria under which study data will be quantitatively	Page 9
			synthesised	
36 37	Data synthesis	<u>#15b</u>	If data are appropriate for quantitative synthesis, describe	Page 9
38 39			planned summary measures, methods of handling data and	
40 41 42			methods of combining data from studies, including any	
43 44 45			planned exploration of consistency (such as I2, Kendall's τ)	
46 47	Data synthesis	<u>#15c</u>	Describe any proposed additional analyses (such as	Page 9,10
48 49 50			sensitivity or subgroup analyses, meta-regression)	
51 52	Data synthesis	<u>#15d</u>	If quantitative synthesis is not appropriate, describe the type	Page 9
53 54 55			of summary planned	
56 57 58	Meta-bias(es)	<u>#16</u>	Specify any planned assessment of meta-bias(es) (such as	Page 8,9
59 60		For pee	r review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

a tool

reporting with
evidence will
reative Comr os://www.goo

1			publication bias across studies, selective reporting within	
2 3			studies)	
4			Studies	
5 6 7	Confidence in	<u>#17</u>	Describe how the strength of the body of evidence will be	Page 9
8 9	cumulative		assessed (such as GRADE)	
10 11 12	evidence			
13 14	None The PRISMA	A-P cheo	cklist is distributed under the terms of the Creative Commons A	ttribution
15 16 17	License CC-BY 4.0	). This c	hecklist can be completed online using <u>https://www.goodreport</u>	<u>ts.org/</u> , a t
18 19	made by the EQUA	ATOR N	etwork in collaboration with Penelope.ai	
20 21				
22				
23 24				
25 26				
26 27				
28				
29 30				
31				
32				
33 34				
34 35				
36				
37				
38 39				
40				
41 42				
42 43				
44				
45				
46 47				
47 48				
49				
50				
51 52				
52 53				
54				
55				
56 57				
57 58				
59				

60

# **BMJ Open**

#### Safety and Efficacy of Mycophenolate Mofetil in Treating NMOSD : a protocol for systematic review and metaanalysis.

Journal:	BMJ Open
Manuscript ID	bmjopen-2020-040371.R2
Article Type:	Protocol
Date Submitted by the Author:	07-Sep-2020
Complete List of Authors:	han, mengyu; Beijing University of Chinese Medicine; China-Japan Friendship Hospital, Ophthalmology Nong, Luqi; Beijing University of Chinese Medicine, Graduate School ; China-Japan Friendship Hospital, Ophthalmology Liu, Ziqiang; Beijing University of Chinese Medicine, Graduate School ; China-Japan Friendship Hospital, Ophthalmology Chen, You; China-Japan Friendship Hospital Chen, Yang; Beijing University of Chinese Medicine Meng, Huan; Beijing University of Chinese Medicine, Graduate School; China-Japan Friendship Hospital, Ophthalmology Qin, Yali; Sun Yat-Sen University Zhongshan Ophthalmic Center Wang, Zhijun; China-Japan Friendship Hospital, ophthalmology department Jin, Ming; China-Japan Friendship Hospital, Ophthalmology
<b>Primary Subject Heading</b> :	Ophthalmology
Secondary Subject Heading:	Neurology, Evidence based practice
Keywords:	OPHTHALMOLOGY, NEUROLOGY, IMMUNOLOGY, Neuro-ophthalmology < NEUROLOGY





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

reliez on

Safety and Efficacy of Mycophenolate Mofetil in Treating NMOSD : a protocol for systematic review and meta-analysis.

Mengyu Han, PhD<sup>a,b</sup>, Luqi Nong, MD<sup>a,b</sup>, Ziqiang Liu, MD<sup>a,b</sup>, You Chen<sup>b</sup>, Yang Chen, MD<sup>a,b</sup>, Huan Meng, MD<sup>a,b</sup>, Yali Qin, MD<sup>c</sup>, Zhi-Jun Wang, MD<sup>b</sup>, Ming Jin MD<sup>b</sup>\*

<sup>a</sup>Beijing University of Chinese Medicine, Beijing 100029, China; <sup>b</sup>Department of Ophthalmology, China-Japan Friendship Hospital, Beijing 100029, China. <sup>c</sup> Sun Yat-Sen University Zhongshan Ophthalmic Center.

\* Correspondence: Ming Jin, Department of Ophthalmology, China-Japan Friendship Hospital, No. 2, Yinghua Donglu, Chaoyang District, Beijing 100029, China (e-mail: jinmingyk@163.com).

#### Abstract

**Introduction** Neuromyelitis optica spectrum disorders (NMOSD) is an inflammatory and heterogeneous astrocyte disorder of the central nervous system (CNS) with the characteristic of higher incidence in women and Asian people. Most patients with NMOSD have a course of recurrence and remission that is prone to cause paralysis and blindness. Several studies have confirmed the efficacy and promising prospect of mycophenolate mofetil (MMF) in the treatment of NMOSD. Yet its therapeutic effect and safety are controversial. Although there has been two published literature that is relevant to the topic of this study, both of them have certain defects, and they can only provide answers about the efficacy or safety of MMF in the treatment of NMOSD from partial perspectives or conclusions. This research aims to perform a direct and comprehensive systematic review and meta-analysis to evaluate MMF's effectiveness and safety in treating NMOSD.

**Methods and analysis** This systematic review will cover all comparative researches, from randomized controlled trials (RCTs) to cohort studies, and case-control study. A relevant literature search will be conducted in PubMed, Web of Science, EMBASE, the Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang Database, China Science and Technology Journal database (VIP) and Chinese Biomedical Literature database (CBM). We will also search registers of clinical trials,

potential gray literature, and abstracts from conferences. There are no limits on language and publication status. The reporting quality and risk of bias will be assessed by two researchers independently. Expanded disability status scales (EDSS), annualized relapse rate (ARR)will be evaluated as the primary outcome. The secondary outcomes will consist of the frequency and severity of adverse events (AEs), best-corrected visual acuity (BCVA), relapse-free rate and time to the next attack. A meta-analysis will be performed using RevMan5.3 software provided by the Cochrane Collaboration and Stata 12.0.

**Ethics and dissemination** Because the data used for this systematic review will be exclusively extracted from published studies, ethical approval and informed consent of patients will not be required. The systematic review will be published in a peer-reviewed journal, presented at conferences and will be shared on social media platforms.

## **PROSPERO registration number:** PROSPERO CRD42020164179.

#### Strengths and limitations of this study:

► This study will carry out an exhaustive literature search to identify studies aimed at evaluating the efficacy and safety of MMF in treating NMOSD.

► One limitation of this study is that differences in patients, interventions and primary outcomes may mean that meta-analysis cannot be performed and there are plans for narrative and meta- analytical syntheses.

► Although we will include studies published in any language, translation difficulties may arise, which will result in the exclusion of these studies.

► The analysis of various sources of heterogeneity and the assessment of risk of bias of the included studies is a critical point for extracting and synthesizing evidence-based conclusions.

**Keywords:** mycophenolate mofetil, neuromyelitis optica spectrum disorders, protocol, systematic review, meta-analysis.

#### 1. Introduction

Neuromyelitis Optica (NMO), also known as Devic disease, is generally considered to be a rare autoimmune astrocyte disorder of the central nervous system (CNS), induced by autoantibodies, dominated by humoral immunity and involving numerous immune

 cells and factors, with optic neuritis(ON) and acute transverse myelitis as typical clinical manifestations.<sup>1</sup> NMO has been known as a subtype of multiple sclerosis (MS) for over 100 years since it was first described and reported.<sup>2</sup> Until 2004, the discovery and confirmation of anti-aquaporin-4 immunoglobulin G (AQP4-IgG) had made substantial progress in pathogenesis, diagnosis, and treatment of NMO.<sup>3 4</sup> The notion of neuromyelitis optica spectrum disorders (NMOSD) was first proposed based on the wide clinical use of specific AQP4-IgG,<sup>4</sup> which mainly referred to the minimal AQP4-IgG positive NMO. However, the deficiencies of the diagnostic criteria of NMO in 2006 and NMOSD in 2007 became prominent with the incremental improvement of the specificity of clinical AQP4-IgG tests. In 2015, a groundbreaking international diagnostic protocol for NMOSD was put forward by the global NMO diagnostic team.<sup>5</sup> NMOSD consists of NMO, ON, longitudinally extensive transverse myelitis and other common cerebral demyelinating syndromes.<sup>5</sup> There are so far no reliable statistics on the worldwide incidence and prevalence of NMOSD. According to the current epidemiological evidence of small samples, the high incidence of this disease is among middle-aged and young women, with the onset age varying from 32 to 41 years old, and the incidence in females is about 10 times that of males.<sup>5</sup> The incidence and prevalence of approximately 0.05-0.40 and 0.52-4.40/100,000 vary from region to region.<sup>6</sup> A populous region of Asia is the region with a high incidence of NMOSD.<sup>7-9</sup> Most NMOSD patients have a recurrence and remission including ON, myelitis, and lesions in special parts of the brain that are vulnerable to cause paralysis and blindness.<sup>5</sup> NMOSD has become one of the most common causes of non-traumatic disability and blindness in young and middle-aged individuals, putting heavy burdens on the life, work and study, as well as the society and economy of various countries.<sup>10</sup> Clinical studies indicate that approximately 1/4 of patients will not be able to walk independently after an average of 5 years of NMO, approximately 10% will be wheelchair-dependent, and more than half of patients will have serious vision loss in at least one eye.11 In particular, ON associated with NMO (NMO-ON) possesses poor recovery even after traditional therapy, which often progresses into significant bilateral visual loss in the long term, leaving behind varying degrees of optic atrophy, which is

#### **BMJ** Open

different from MS.1213

Currently, there are no standardized guidelines for the clinical management of NMOSD. The class of NMOSD drugs is commonly referred to as disease-modifying drugs,<sup>14</sup> and the treatment is split into two stages: the acute phase and the period of remission. The former is based on corticosteroids to reduce the severity and frequency of acute attacks that include intravenous corticosteroids (IVCSs), plasma exchange (PLEX), and immunoglobulin. Immunosuppressive agents, including mycophenolate mofetil (MMF), azathioprine (AZA), cyclophosphamide, methotrexate, mitoxantrone, tacrolimus, cyclosporine, and monoclonal antibodies, are frequently used during the process of recovery to avoid recurrence and to mitigate the progression of neurological impairment.<sup>15 16</sup> Although AZA and rituximab are recommended as first-line therapies obtained from clinical trials and expert opinion from the published guidelines for NMOSD,<sup>16</sup> there are still adverse events (AEs) such as disease recurrence and myelosuppression that results in drug withdrawal or replacement of these drugs in patients with NMOSD.<sup>17</sup> Other AEs for Rituximab have also been reported in recent years such as infusion reactions, infection, and even death, <sup>18-20</sup> and its clinical application has been constrained by such factors as high price.<sup>18 21</sup> Therefore, a better immunosuppressant for the treatment of NMOSD is urgently needed. The application of MMF in NMOSD is still under investigation and is recommended as second-line treatments,<sup>16</sup> but some studies have verified MMF's efficacy and promising potential,<sup>21-</sup> <sup>24</sup> and only a few AEs were published.<sup>21</sup> <sup>22</sup> Especially, additional studies have also indicated that MMF was more effective and triggered less AEs than AZA.<sup>25 26</sup> In patients experiencing AEs or poor response to AZA, MMF is recommended as an alternative therapy.<sup>16</sup>

Although MMF is increasingly employed in NMOSD, there is still controversy about its related harms and benefits. At present, there are mainly two published articles that are relevant to the topic and purpose of our research.<sup>27 28</sup> Nevertheless, these two studies have some imperfections in the direct evaluation of the efficacy and safety of MMF in the treatment of NMOSD patients. For example, the Espiritu and Pasco paper did not quantitatively evaluate the efficacy of MMF in the treatment of NMOSD and did not

compare the AEs of MMF with other drugs in the treatment of NMOSD. Additionally, Huang et al. 's research was a network meta-analysis and the literature related to MMF in this paper was three observational studies that made the number of included studies and closed loops per comparison were few, which might lower the reliability of the findings. In our study, the database we searched includes not only the English database but also the Chinese database. The retrieval time is limited to June 2020, and we will add 3 retrospective studies involving 471 patients with NMOSD,<sup>29-31</sup> which makes the retrieval literature more comprehensive. At the same time, the conclusions of the previously published literature about the clinical effect of MMF were inconsistent. Poupart argued that RTX was clinically better tolerated than MMF.<sup>30</sup> But Huang et al argued that MMF had the best drug tolerance and was superior to RTX.<sup>31</sup> We expect our research to help solve this problem as well.

#### 2. Methods

 This protocol has been registered on PROSPERO (registration number: CRD 42020164179). Our protocol will follow the Meta-analysis of Observational Studies in Epidemiology (MOOSE),<sup>32</sup> the Cochrane Handbook for Systematic Reviews of Interventions and the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocol (PRISMA-P) statement guidelines. <sup>33 34</sup>

#### 2.1 Inclusion criteria for study selection

#### 2.1.1 Types of studies

All comparative researches, from randomized controlled trials (RCTs) to cohort studies, and case-control study, covering at least two interventions, will be included. The current clinical trial results will be objectively integrated, which is conducive to the evaluation of the efficacy and safety of MMF for NMOSD. We will exclude reviews, qualitative studies, animal trials, laboratory studies and studies only involving one intervention.

#### 2.1.2 Types of patients

Patients diagnosed as having NMOSD will be included in this study.<sup>5 35</sup> There will be no restrictions based on other conditions, such as age at onset, sex, ethnicity, educational or economic status, number of pre-treatment relapses, previous treatment, duration of illness, disease severity, and baseline expanded disability status scales (EDSS), AQP4-IgG serological status.

#### 2.1.3 Types of interventions

Trials comparing MMF to placebo or any other active substances, including AZA, cyclophosphamide, methotrexate, mitoxantrone, tacrolimus, cyclosporine, and monoclonal antibodies, will be considered. Besides, the types, dosage, and frequency of MMF were not limited. Studies that MMF with combination therapy fail to objectively evaluate the efficacy and safety of MMF will be eliminated.

#### 2.1.4 Types of outcome measures

#### 2.1.4.1 Primary outcomes

- (1) EDSS: Disability progression was characterized as an increase in the Kurtzke EDSS by at least 1 point above the pre-treatment score if baseline score < 5.5, and by at least half-point if baseline score > 5.5. Outcome measured was the mean changes of EDSS before and after MMF treatment.<sup>36 37</sup>
- (2) Annualized relapse rate (ARR): Relapse is equivalent to a neurologic symptom lasting for > 24 h, which occurs at least 30 days after the onset of a preceding event. ARR is computed as the number of relapses divided by the time in years (days). Post-treatment ARR was contrasted with pre-treatment ARR. <sup>38</sup>

#### 2.1.4.2 Secondary outcomes

- The frequency and extent of AEs: During treatment and follow-up periods, any symptomatic events which had a possible, probable or definite causal relationship to MMF treatment were defined as AEs.
- (2) Relapse-free rate: The absence of relapse during the observation period of the study reported as percentage per study.<sup>35</sup>
- (3) Best-corrected visual acuity (BCVA): BCVA was measured using a standardized test, such as the ETDRS chart, Snellen chart or similar method, and other visual acuity measures would be allowed if findings could be justified as well as validated concerning accepted relevant standard measures. Outcome measured was the mean change of BCVA from before and after MMF treatment.<sup>39</sup>
- (4) Time to the next attack.

#### 2.1.4.3 Security index

The safety was assessed by the occurrence of AEs. Any unexpected events that occurred during the studies will be recorded on an AEs report form, including: <sup>28</sup>

- (1) General physical examination (temperature, pulse, respiration, blood pressure).
- (2) Routine examination of blood, urine and stool.
- (3) Liver and kidney function examination.
- (4) Gastrointestinal discomfort.
- (5) Hair loss or Alopecia.

- (6) Allergic or Anaphylactoid reactions.
- (7) Drug discontinued due to drug-related AEs.
- (8) Possible AEs and related detection indicators.

#### 2.2 Search methods for the identification of studies

#### 2.2.1 Electronic searches

A relevant literature search by sensitive search strategies was conducted using the following electronic databases from their inception to June 31, 2020: PubMed, Web of Science, EMBASE, the Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang Database, China Science and Technology Journal database (VIP) and Chinese Biomedical Literature database (CBM). Search methods of MeSH terms with free words were applied in English databases. The related terms are as follows: Participants (neuromyelitis optica, neuromyelitis optica spectrum disorders, Devic Neuromyelitis Optica, Devic's Neuromyelitis Optica, Devic's Syndrome, NMO spectrum disorders), Intervention (mycophenolic acid, mycophenolate mofetil, "mofetil, mycophenolate", cellcept, myfortic, RS61443). The search strategy for PubMed is described in Table 1, which will include all search terms, and other searches will be carried out based on those results. This will be suitably adapted to search in the other databases. There are no limits on language and publication status.

#### 2.2.2 Searching other resources

we will also search PROSPERO, the International Clinical Trials Registry Platform (ICTRP), ClinicalTrials.gov, dissertations, and gray literature to identify systematic reviews or clinical trials related to mycophenolate mofetil and neuromyelitis optica spectrum disorders. Manual searches will be conducted for related journals and

#### **BMJ** Open

conference processes. We will also review papers and bibliographies included in the trials.

2.3 Data collection and analysis

#### 2.3.1 Selection of studies

Two reviewers (MYH and ZQL) will independently browse the titles and abstracts of all of the retrieved records to distinguish and exclude any irrelevant articles. Studies only related to human subjects are to be included. Any discord will be resolved by discussion between the two authors and an arbiter (MJ). The selection procedure for the study is shown in a PRISMA flow chart (Fig. 1).

#### 2.3.2 Data extraction and management

Based on the inclusion criteria, a standard form of data collection will be produced prior to data extraction. Search results will be entered into an EndNote X9 database and duplicate entries removed. Two authors (MYH and ZQL) will extract the data of interest from the eligible study and enter the data extraction sheet as follows: The basic characteristics of each study (study design or methods, author, title, source/journal, time of publication, country, hospital setting); participants characteristics (average age, gender, sample size, inclusion and exclusion criteria, baseline situation); Interventions (type, duration, frequency and dosage of MMF, randomization, allocation concealment, blinding methods); Comparators (AZA, tacrolimus, cyclosporine, monoclonal antibodies, and placebo, etc); Outcomes (measures, main outcomes, security indexes, and follow up); If funded, it will also be recorded. When the consensus on data extraction is not available through discussion, the third reviewer (MJ) will make a decision.

#### 2.3.3 Assessment of risk of bias

Two authors (Yang Chen and LQN) will independently estimate the risk and bias using the Cochrane risk of bias (ROB) assessment tool for RCTs.<sup>40</sup> Methodological quality evaluation of the included observational studies will be carried out using the Newcastle–Ottawa Scale (NOS).<sup>41</sup> The RevMan software program (V.5.3) will document the selected details of each study.<sup>42</sup>

#### 2.3.4 Measures of treatment effect

The risk ratio (RR) and 95% confidence interval (CI) will be used to analyze dichotomous data and calculate the treatment effect. A weighted mean difference (WMD) or a standard mean difference (SMD) with 95% CIs will be used to analyze continuous outcomes.

#### 2.3.5 Unit of analysis issue

 We will only extract the 1st experimental period data of crossover trials to avoid carryover effects. In the meantime, given that there are multiple intervention groups in trials, we will combine all analogous groups into a single pairwise comparison to avoid a unit of analysis issue.

#### 2.3.6 Management of missing data

Reviewer (YLQ and You Chen) will contact the appropriate author of the included trials for clarification or more details via email and telephone if necessary. The missing data will be deleted, if there is no response from the author. That will be addressed in the discussion in this case. If quantitative data were not available, then the qualitative analysis should be used.

#### 2.3.7 Assessment of heterogeneity and data synthesis

We will use all of the case data for the analysis data. Heterogeneity will be tested with a standard Chisquare test.<sup>43</sup> To quantify the impact of the statistical heterogeneity on the systematic review, the I<sup>2</sup> value will be applied to calculate and present the heterogeneity degree. If P>0.1, I<sup>2</sup><50%, it is considered that there is no heterogeneity between the trials, and the model of fixed effect will be used, otherwise, the model of random effect will be adopted. All statistical analyzes will be performed using the RevMan5.3 software provided by the Cochrane Collaboration. Using the software to obtain forest plots and test the heterogeneity between the included studies. The Grades of Recommendation, Assessment, Development and Evaluation (GRADE) will be used to assess the meta-analysis findings and determine the quality of evidence. Where meta-analysis may not be not feasible due to lack of clinical trials or heterogeneity, systematic narrative synthesis will be adopted.

#### 2.3.8 Assessment of reporting biases

When 10 or more studies are included in a meta-analysis, we will evaluate funnel plot

#### **BMJ** Open

asymmetry for reporting biases and small-study effects using Egger's method.<sup>44</sup> For Egger's test, P value of greater than 0.05 was determined as no significant publishing bias or small-study effects in studies. As funnel plot asymmetry does not necessarily suggest reporting bias, we will attempt to recognize potential causes for the asymmetry, including poor methodological quality and true heterogeneity of studies.

#### 2.3.9 Subgroup analysis

Upon detection of heterogeneity, a subgroup analysis will be carried out to judge the source of heterogeneity. The criteria for a subgroup analysis are as follows:

- (1) Age.
- (2) Type of MMF.
- (3) Research type.
- (4) Participation population.
- (5) Type of control interventions.
- (6) Intervention dosage, frequency and duration.
- (7) AQP4-IgG serological status.

#### 2.3.10 Sensitivity analysis

The ROB tool will be used to estimate methodological quality in the case of sufficient data from trials. Sensitivity analysis will be performed to determine the robustness of aggregate estimates and to detect whether any single study accounts for a substantial proportion of heterogeneity by eliminating the included studies from the summary review one by one. If low-quality articles are deleted, then a second meta-analysis will be carried out. Comparison and discussion of the results and effect size of the two meta-analyses will be held. <sup>45</sup>

**2.4 Patient and public involvement** Patients and/or the public will not participate in the study. However, once scientific publications disseminate our findings, they are circulated across social networks so that our conclusions will affect the actions of neuro-ophthalmologists and health policymakers.

#### Discussion

Pathogenesis, diagnosis and treatment of NMO are rapidly growing areas of research as AQP4-IgG were first identified. Patients with NMOSD should receive standardized

and personalized immunotherapy as soon as possible, as any further acute episodes may result in severe and often irreversible disability. The challenges in discovering new and better drugs for NMO are the rareness of the disease and the unfavorable prognosis in many cases, which make clinical studies with placebo groups difficult.<sup>16</sup> Many studies have confirmed the efficacy and promising prospect of MMF in the treatment of NMOSD,<sup>21-24</sup> and only a few AEs were reported. <sup>21 22</sup> Additional studies have also indicated that MMF was more effective and triggered less AEs than AZA.<sup>25 26</sup> However, its therapeutic effect and safety remain controversial. Although there has been two published literature that is relevant to the topic of this study,<sup>27 28</sup> both of them have certain defects, and they can only provide answers about the efficacy or safety of MMF in the treatment of NMOSD from partial perspectives or conclusions. If our paper is completed, it will be a currently searchable protocol for a traditional meta-and systematic review that directly and synthetically evaluates the efficacy and safety of MMF in the treatment of NMOSD. One of the strengths of this protocol will use a comprehensive search strategy of published literature. The overall data used in each analysis will be evaluated qualitatively and quantitatively. The sources of heterogeneity and different subgroups of the articles will be analyzed to comprehensively evaluate the efficacy and safety of MMF in the treatment of NMOSD, and to increase the credibility of the article content and conclusions. We expect that this systematic review will benefit patients with NMOSD, physicians, health care administrators and policymakers.

#### Author contributions

MYH conceived and designed the protocol, and MYH drafted the protocol manuscript. MYH developed the search strategy, with input from ZQL and LQN. MYH and ZQL planned data extraction. MYH, Yang Chen and ZJW planned the quality appraisal of all included studies. MYH, ZQL, LQN, Yang Chen, HM, You Chen, ZJW, YLQ and MJ critically revised the manuscript for methodological and intellectual content. All authors approved the final version.

#### **BMJ** Open

Conceptualizatio	on: Meng-Yu Han, Zi-Qiang Liu, Zhi-Jun Wang, Ming Jin.
<b>Data curation:</b> N	Meng-Yu Han, Zi-Qiang Liu, Lu-Qi Nong, Huan Meng.
Formal analysis	: Meng-Yu Han, Zi-Qiang Liu.
Funding acquisi	tion: Meng-Yu Han.
Investigation: M	ling Jin.
Methodology: M	leng-Yu Han, Zi-Qiang Liu, Lu-Qi Nong, You Chen.
Project administ	tration: Ming Jin.
Resources: Men	g-Yu Han, Zi-Qiang Liu, Lu-Qi Nong, Ming Jin.
Software: Meng-	-Yu Han, Zi-Qiang Liu, Lu-Qi Nong.
Supervision: Me	eng-Yu Han, Zhi-Jun Wang, Ming Jin.
Validation: Hua	n Meng, Yang Chen, Ya-li Qin, Ming Jin.
Visualization: H	uan Meng, Yang Chen, Ya-li Qin, Ming Jin.
Writing – origin	al draft: Meng-Yu Han, Zi-Qiang Liu, Lu-Qi Nong, Ming Jin.
Writing – reviev	v & editing: Meng-Yu Han, Zi-Qiang Liu, Lu-Qi Nong, Ming Jin.

**Funding:** This study was funded by the National Natural Science Foundation of China (No. 81574029). The funders had no role in the design, execution, or writing of the study.

Competing interests: None declared.

#### Reference

[1] Jasiak-Zatonska M, Kalinowska-Lyszczarz A, Michalak S, & Kozubski W. The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives. International J Molecular Sciences 2016;17(3):273.

[2] Jarius S, Wildemann B. On the contribution of Thomas Clifford Allbutt, F.R.S., to the early history of neuromyelitis optica. J Neurol 2013; 260:100-104.

[3] Yang X, Ransom R, Ma J F. The role of AQP4 in neuromyelitis optica: more answers, more questions. Neuroimmunol 2016;298:63-70.

[4] Wingerchuk D M, Lennon V A, Lucchinetti C F, et al. The spectrum of

neuromyelitis optica. The Lancet Neurology 2007;6(9):805-815.

 [5] Wingerchuk D M, Banwell B, Bennett J L, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85(2):177-189.

[6] Pandit L, Asgari N, Apiwattanakul M, et al. Demographic and clinical features of neuromyelitis optica: A review. Mult Scler 2015;21(7):845-853.

[7] Bukhari W, Prain KM, Waters P, et al. Incidence and Prevalence of NMOSD in Australia and New Zealand. J Neurol Neurosurg Psychiatry 2017;88(8): 632-638.
[8] Viswanathan S, WallL M. A nationwide epidemiological study on the prevalence of multiple sclerosis and neuromyelitis optica spectrum disorder with important multi-ethnic differences in Malaysia. Muh Scler 2019;25(11): 1452-1461.

[9] Miyamoto K, Fujihara K, Kira J1, eta1. Nationwide epidemiological study of neuromyelitis optician Japan. J Neurol Neurosurg Psychiatry 2018;89(6): 667-668.

[10] Wingerchuk D M, Hogancamp W F, O'Brien P C, et al. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53,1107.

[11] Jiao Y, Fryer JP, Lennon VA, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology 2013;81:1197-1204.

[12] Drori T, ChapmanJ. Diagnosis and classification of neuromyelitis optica (Devic's syndrome). Autoimmun Rev 2014;13(4-5):531–533.

[13] Optic Neuritis Study Group. Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial. Ophthalmology 2008;115(6): 1079-1082.

[14] Papadopoulos MC, Bennett JI, Verkman AS. Treatment of neuromyelitis optica state-of-the-art and emerging therapies. Nat Rev Neurol 2014;10(9):493-506.

[15] Wu Y, Zhong L, Geng J.Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models. Mult Scler Relat disord 2019;27(1):412-418.

[16] Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 2014; 261(1):1-16.

[17] Elsone L, Kitley J, Luppe S, et al. Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica

#### **BMJ** Open

spectrum disorder patients: a multicentre retrospective observational study from the UK [J]. Mult Scler 2014;20(11):1533-1540.

[18] Torres J, Pruitt A, Balcer L, et al. Analysis of the treatment of neuromyelitis optica.J Neurol Sci 2015;351(1-2):31-35.

[19] Annovazzi P, Capobianco M, Moiola L, et al. Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study. J Neurol 2016; 263(9): 1727-1735.

[20] Collongues, N, de Seze, J. An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica. Ther Adv Neurol Disord 2016;9(3):180-188.

[21] Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 2009; 66(9):1128-33.

[22] Huh S Y, Kim S H, Hyun J W, et al. Mycophenolate Mofetil in the Treatment of Neuromyelitis Optica Spectrum Disorder. JAMA Neurology 2014;71(11):1372-1378.

[23] Chen H, Zhang Y, Shi Z, et al. The Efficacy and Tolerability of Mycophenolate Mofetil in Treating Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder in Western China. Clin Neuropharmacol 2016; 39(2):81-87.

[24] Jiao Y, Cui L, Zhang W, et al. Dose effects of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorders: a case series study. BMC Neurology 2018;18(1):47.

[25] Chen H, Qiu W, Zhang Q, et al. Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder. Eur J Neurol 2017;24(1):219-226.

[26] Yang Y, Wang C J, Wang B J, et al. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder. J Neurol Sci 2018;385:192-197.

[27] Huang W, Wang L, Zhang B, Zhou L, Zhang T, Quan C. Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis optica spectrum disorders: A systematic review and network meta-

analysis. Mult Scler Relat Disord 2019;35:246-252.

 [28] Espiritu AI, Pasco PMD. Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: A systematic review and meta-analysis. Mult Scler Relat Disord 2019;33(8):22-32.

[29] Zhou Y, Zhong X, Shu Y, et al. Clinical course, treatment responses and outcomes in Chinese paediatric neuromyelitis optica spectrum disorder. Mult Scler Relat Disord 2019;28:213-220.

[30] Poupart J, Giovannelli J, Deschamps R, et al. Evaluation of efficacy and tolerability of first-line therapies in NMOSD. Neurology 2020;94(15):e1645-e1656..

[31] Shi Z, Du Q, Chen H, et al. Effects of immunotherapies and prognostic predictors in neuromyelitis optica spectrum disorder: a prospective cohort study. J Neurol 2020; 267(4):913-924.

[32] Stroup DF, Berlin JA, Morton SC, et al, Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 283(15);2008-2012.

[33] Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;350:7647.

[34] Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.

[35] Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66 (10), 1485-1489.

[36] Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurol Int 1983;33 (11):1444-1452.

[37] Enriquez C A G, Espiritu A I, Pasco P M D. Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: A systematic review. Journal of Neuroimmunology 2019;332(7):126-134.

[38] Lavery AM, Verhey LH, Waldman AT. Outcome measures in relapsing-remitting multiple sclerosis: capturing disability and disease progression in clinical trials. Mult Scler Int 2014;2014, 262350.

[39] Squires H, Poku E, Bermejo I, et al. A systematic review and economic evaluation

Page 17 of 23

#### **BMJ** Open

of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults. Health Technol Assess 2017;21(68):1-170. [40] Savović J, Weeks L, Sterne JA, et al. Evaluation of the Cochrane Collaboration's tool for assessing the risk of bias in randomized trials: focus groups, online survey, proposed recommendations and their implementation. Syst Rev 2014;15:37.

[41] Wells G, Shea B, O'Connell D, et al. The Newcastle–Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Mult Scler 13(8); 968-974.

[42] Collaboration RTC. Review Manager (RevMan). 5.0. COPENHAGEN: THE NORDIC COCHRANE COLLABORATION,2008.

[43] Chen B, Benedetti A. Quantifying heterogeneity in individual participant data meta-analysis with binary outcomes. Syst Rev 2017;6:243.

[44] Egger M, Smith GD, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.

[45] Shih KC, Lun CN, Jhanji V, et al. Systematic review of randomized controlled trials in the treatment of dry eye disease in Sjogren syndrome. J Inflamm (LOND) 2017; 14:26.

Table 1 Search strategy use	ed in PubMed database.
-----------------------------	------------------------

Number	Search terms			
#1	("Neuromyelitis Optica"[Mesh]) OR (((((neuromyelitis optica			
	spectrum disorders [Title/Abstract]) OR Devic Neuromyelitis Optica			
	[Title/Abstract]) OR Devic's Neuromyelitis Optica [Title/Abstract])			
	OR Devic's Syndrome [Title/Abstract]) OR NMO spectrum disorders			
	[Title/Abstract])			
#2	("Mycophenolic Acid"[Mesh]) OR (((((Mycophenolate Mofetil			
	[Title/Abstract]) OR "Mofetil, Mycophenolate" [Title/Abstract]) OR			
	Cellcept [Title/Abstract]) OR Myfortic [Title/Abstract]) OR RS61443			
	[Title/Abstract])			

Page 18 of 23

#3	#1 and #2
Figure1. 7	The PRISMA flow chart of the selection process.




Figure1. The PRISMA flow chart of the selection process.

BMJ Open: first published as 10.1136/bmjopen-2020-040371 on 30 November 2020. Downloaded from http://bmjopen.bmj.com/ on April 23, 2024 by guest. Protected by copyright

# Reporting checklist for protocol of a systematic review.

Based on the PRISMA-P guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMA-Preporting guidelines, and cite them as:

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.

			Page
		Reporting Item	Number
Title			
Identification	<u>#1a</u>	Identify the report as a protocol of a systematic review	Page 1
Update	<u>#1b</u>	If the protocol is for an update of a previous systematic	
		review, identify as such	
	For pe	eer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2 3	Registration			
4 5 6 7 8		<u>#2</u>	If registered, provide the name of the registry (such as	Page 2
			PROSPERO) and registration number	
9 10 11 12	Authors			
13 14	Contact	<u>#3a</u>	Provide name, institutional affiliation, e-mail address of all	Page 1
15 16			protocol authors; provide physical mailing address of	
17 18 19			corresponding author	
20 21	Contribution	<u>#3b</u>	Describe contributions of protocol authors and identify the	Page1,11,12
22 23			guarantor of the review	
24 25 26 27	Amendments			
28 29		<u>#4</u>	If the protocol represents an amendment of a previously	
30 31 32			completed or published protocol, identify as such and list	
33 34			changes; otherwise, state plan for documenting important	
35 36			protocol amendments	
37 38				
39 40	Support			
41 42 43 44 45 46 47	Sources	<u>#5a</u>	Indicate sources of financial or other support for the review	Page 12
	Sponsor	<u>#5b</u>	Provide name for the review funder and / or sponsor	Page 12
48 49	Role of sponsor or	<u>#5c</u>	Describe roles of funder(s), sponsor(s), and / or	Page 12
50 51 52	funder		institution(s), if any, in developing the protocol	
53 54 55	Introduction			
56 57 58	Rationale	<u>#6</u>	Describe the rationale for the review in the context of what	Page 2,3,4,5
59 60		For pee	er review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17			is already known	
	Objectives	<u>#7</u>	Provide an explicit statement of the question(s) the review	Page 5,6,7
			will address with reference to participants, interventions,	
			comparators, and outcomes (PICO)	
	Methods			
	Eligibility criteria	<u>#8</u>	Specify the study characteristics (such as PICO, study	Page 7,8
			design, setting, time frame) and report characteristics	
18 19 20			(such as years considered, language, publication status) to	
20 21 22			be used as criteria for eligibility for the review	
23 24	Information	#9	Describe all intended information sources (such as	Page 7,8
25 26	sources	<u></u>	electronic databases, contact with study authors, trial	
27 28 29	ocuroco		registers or other grey literature sources) with planned	
30 31			dates of coverage	
32 33				
34 35	Search strategy	<u>#10</u>	Present draft of search strategy to be used for at least one	Page 7
36 37			electronic database, including planned limits, such that it	
38 39 40			could be repeated	
41 42 43	Study records -	<u>#11a</u>	Describe the mechanism(s) that will be used to manage	Page 8
43 44 45 46 47 48 49 50 51 52	data management		records and data throughout the review	
	Study records -	<u>#11b</u>	State the process that will be used for selecting studies	Page 8
	selection process		(such as two independent reviewers) through each phase	
			of the review (that is, screening, eligibility and inclusion in	
53 54			meta-analysis)	
55 56 57	Study records -	<u>#11c</u>	Describe planned method of extracting data from reports	Page 8,9
58 59 60		For pee	er review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

Page 23 of 23

#### BMJ Open

1	data collection		(such as piloting forms, done independently, in duplicate),	
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 8 39 30 31 32 33 34 35 36 37 38 39 30 31 32 33 34 35 36 37 38 39 30 31 32 33 34 35 36 37 38 39 30 31 32 32 32 32 32 32 32 32 32 32	process		any processes for obtaining and confirming data from	
			investigators	
	Data items	<u>#12</u>	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	Page 8
	Outcomes and prioritization	<u>#13</u>	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	Page 6,7
	Risk of bias in	<u>#14</u>	Describe anticipated methods for assessing risk of bias of	Page 8
	individual studies		individual studies, including whether this will be done at	
			the outcome or study level, or both; state how this	
			information will be used in data synthesis	
	Data synthesis	<u>#15a</u>	Describe criteria under which study data will be quantitatively synthesised	Page 9
	Data synthesis	<u>#15b</u>	If data are appropriate for quantitative synthesis, describe	Page 9
40 41			planned summary measures, methods of handling data	-
42 43 44 45 46 47 48 49 50			and methods of combining data from studies, including any	
			planned exploration of consistency (such as I2, Kendall's	
			т)	
51 52	Data synthesis	<u>#15c</u>	Describe any proposed additional analyses (such as	Page 9,10
53 54 55 56 57 58			sensitivity or subgroup analyses, meta-regression)	
	Data synthesis	<u>#15d</u>	If quantitative synthesis is not appropriate, describe the	Page 9
59 60		For pe	er review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2			type of summary planned	
3 4 5 6 7 8	Meta-bias(es)	<u>#16</u>	Specify any planned assessment of meta-bias(es) (such	Page 8,9,10
			as publication bias across studies, selective reporting	
			within studies)	
7	License CC-BY 4.0	. This c		
54 55 56				
57 58				
59 60		For pee	er review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

# **BMJ Open**

# Safety and Efficacy of Mycophenolate Mofetil in Treating Neuromyelitis Optica Spectrum Disorders : a protocol for systematic review and meta-analysis.

Journal:	BMJ Open		
Manuscript ID	bmjopen-2020-040371.R3		
Article Type:	Protocol		
Date Submitted by the Author:	12-Oct-2020		
Complete List of Authors:	han, mengyu; Beijing University of Chinese Medicine; China-Japan Friendship Hospital, Ophthalmology Nong, Luqi; Beijing University of Chinese Medicine, Graduate School ; China-Japan Friendship Hospital, Ophthalmology Liu, Ziqiang; Beijing University of Chinese Medicine, Graduate School ; China-Japan Friendship Hospital, Ophthalmology Chen, You; China-Japan Friendship Hospital Chen, Yang; Beijing University of Chinese Medicine Meng, Huan; Beijing University of Chinese Medicine, Graduate School; China-Japan Friendship Hospital, Ophthalmology Qin, Yali; Sun Yat-Sen University Zhongshan Ophthalmic Center Wang, Zhijun; China-Japan Friendship Hospital, ophthalmology department Jin, Ming; China-Japan Friendship Hospital, Ophthalmology		
<b>Primary Subject Heading</b> :	Ophthalmology		
Secondary Subject Heading:	Neurology, Evidence based practice		
Keywords:	OPHTHALMOLOGY, NEUROLOGY, IMMUNOLOGY, Neuro-ophthalmology < NEUROLOGY		





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

reliez on

Safety and Efficacy of Mycophenolate Mofetil in Treating Neuromyelitis Optica Spectrum Disorders : a protocol for systematic review and meta-analysis.

Mengyu Han, PhD<sup>a,b</sup>, Luqi Nong, MD<sup>a,b</sup>, Ziqiang Liu, MD<sup>a,b</sup>, You Chen<sup>b</sup>, Yang Chen, MD<sup>a,b</sup>, Huan Meng, MD<sup>a,b</sup>, Yali Qin, MD<sup>c</sup>, Zhi-Jun Wang, MD<sup>b</sup>, Ming Jin MD<sup>b</sup>\*

<sup>a</sup>Beijing University of Chinese Medicine, Beijing 100029, China; <sup>b</sup>Department of Ophthalmology, China-Japan Friendship Hospital, Beijing 100029, China. <sup>c</sup> Sun Yat-Sen University Zhongshan Ophthalmic Center.

\* Correspondence: Ming Jin, Department of Ophthalmology, China-Japan Friendship Hospital, No. 2, Yinghua Donglu, Chaoyang District, Beijing 100029, China (e-mail: jinmingyk@163.com).

#### Abstract

 **Introduction** Neuromyelitis optica spectrum disorders (NMOSD) is an inflammatory and heterogeneous astrocyte disorder of the central nervous system (CNS) with the characteristic of higher incidence in women and Asian people. Most patients with NMOSD have a course of recurrence and remission that is prone to cause paralysis and blindness. Several studies have confirmed the efficacy and promising prospect of mycophenolate mofetil (MMF) in the treatment of NMOSD. Yet its therapeutic effect and safety are controversial. Although there has been two published literature that is relevant to the topic of this study, both of them have certain defects, and they can only provide answers about the efficacy or safety of MMF in the treatment of NMOSD from partial perspectives or conclusions. This research aims to perform a direct and comprehensive systematic review and meta-analysis to evaluate MMF's effectiveness and safety in treating NMOSD.

**Methods and analysis** This systematic review will cover all comparative researches, from randomized controlled trials (RCTs) to cohort studies, and case-control study. A relevant literature search will be conducted in PubMed, Web of Science, EMBASE, the Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang Database, China Science and Technology Journal database (VIP) and Chinese Biomedical Literature database (CBM) from their inception to June 31, 2020. We will

also search registers of clinical trials, potential gray literature, and abstracts from conferences. There are no limits on language and publication status. The reporting quality and risk of bias will be assessed by two researchers independently. Expanded disability status scales (EDSS), annualized relapse rate (ARR)will be evaluated as the primary outcome. The secondary outcomes will consist of the frequency and severity of adverse events (AEs), best-corrected visual acuity (BCVA), relapse-free rate and time to the next attack. A meta-analysis will be performed using RevMan5.3 software provided by the Cochrane Collaboration and Stata 12.0.

**Ethics and dissemination** Because the data used for this systematic review will be exclusively extracted from published studies, ethical approval and informed consent of patients will not be required. The systematic review will be published in a peer-reviewed journal, presented at conferences and will be shared on social media platforms.

# **PROSPERO registration number:** PROSPERO CRD42020164179.

## Strengths and limitations of this study:

► This study will carry out an exhaustive literature search to identify studies aimed at evaluating the efficacy and safety of MMF in treating NMOSD.

► One limitation of this study is that differences in patients, interventions and primary outcomes may mean that meta-analysis cannot be performed and there are plans for narrative and meta- analytical syntheses.

► Although we will include studies published in any language, translation difficulties may arise, which will result in the exclusion of these studies.

► The analysis of various sources of heterogeneity and the assessment of risk of bias of the included studies is a critical point for extracting and synthesizing evidence-based conclusions.

**Keywords:** mycophenolate mofetil, neuromyelitis optica spectrum disorders, protocol, systematic review, meta-analysis.

#### 1. Introduction

Neuromyelitis Optica (NMO), also known as Devic disease, is generally considered to be a rare autoimmune astrocyte disorder of the central nervous system (CNS), induced by autoantibodies, dominated by humoral immunity and involving numerous immune

 cells and factors, with optic neuritis(ON) and acute transverse myelitis as typical clinical manifestations.<sup>1</sup> NMO has been known as a subtype of multiple sclerosis (MS) for over 100 years since it was first described and reported.<sup>2</sup> Until 2004, the discovery and confirmation of anti-aquaporin-4 immunoglobulin G (AQP4-IgG) had made substantial progress in pathogenesis, diagnosis, and treatment of NMO.<sup>3 4</sup> The notion of neuromyelitis optica spectrum disorders (NMOSD) was first proposed based on the wide clinical use of specific AQP4-IgG,<sup>4</sup> which mainly referred to the minimal AQP4-IgG positive NMO. However, the deficiencies of the diagnostic criteria of NMO in 2006 and NMOSD in 2007 became prominent with the incremental improvement of the specificity of clinical AQP4-IgG tests. In 2015, a groundbreaking international diagnostic protocol for NMOSD was put forward by the global NMO diagnostic team.<sup>5</sup> NMOSD consists of NMO, ON, longitudinally extensive transverse myelitis and other common cerebral demyelinating syndromes.<sup>5</sup> There are so far no reliable statistics on the worldwide incidence and prevalence of NMOSD. According to the current epidemiological evidence of small samples, the high incidence of this disease is among middle-aged and young women, with the onset age varying from 32 to 41 years old, and the incidence in females is about 10 times that of males.<sup>5</sup> The incidence and prevalence of approximately 0.05-0.40 and 0.52-4.40/100,000 vary from region to region.<sup>6</sup> A populous region of Asia is the region with a high incidence of NMOSD.<sup>7-9</sup> Most NMOSD patients have a recurrence and remission including ON, myelitis, and lesions in special parts of the brain that are vulnerable to cause paralysis and blindness.<sup>5</sup> NMOSD has become one of the most common causes of non-traumatic disability and blindness in young and middle-aged individuals, putting heavy burdens on the life, work and study, as well as the society and economy of various countries.<sup>10</sup> Clinical studies indicate that approximately 1/4 of patients will not be able to walk independently after an average of 5 years of NMO, approximately 10% will be wheelchair-dependent, and more than half of patients will have serious vision loss in at least one eye.11 In particular, ON associated with NMO (NMO-ON) possesses poor recovery even after traditional therapy, which often progresses into significant bilateral visual loss in the long term, leaving behind varying degrees of optic atrophy, which is

#### **BMJ** Open

different from MS.1213

Currently, there are no standardized guidelines for the clinical management of NMOSD. The class of NMOSD drugs is commonly referred to as disease-modifying drugs,<sup>14</sup> and the treatment is split into two stages: the acute phase and the period of remission. The former is based on corticosteroids to reduce the severity and frequency of acute attacks that include intravenous corticosteroids (IVCSs), plasma exchange (PLEX), and immunoglobulin. Immunosuppressive agents, including mycophenolate mofetil (MMF), azathioprine (AZA), cyclophosphamide, methotrexate, mitoxantrone, tacrolimus, cyclosporine, and monoclonal antibodies, are frequently used during the process of recovery to avoid recurrence and to mitigate the progression of neurological impairment.<sup>15 16</sup> Although AZA and rituximab are recommended as first-line therapies obtained from clinical trials and expert opinion from the published guidelines for NMOSD,<sup>16</sup> there are still adverse events (AEs) such as disease recurrence and myelosuppression that results in drug withdrawal or replacement of these drugs in patients with NMOSD.<sup>17</sup> Other AEs for Rituximab have also been reported in recent years such as infusion reactions, infection, and even death, <sup>18-20</sup> and its clinical application has been constrained by such factors as high price.<sup>18 21</sup> Therefore, a better immunosuppressant for the treatment of NMOSD is urgently needed. The application of MMF in NMOSD is still under investigation and is recommended as second-line treatments,<sup>16</sup> but some studies have verified MMF's efficacy and promising potential,<sup>21-</sup> <sup>24</sup> and only a few AEs were published.<sup>21</sup> <sup>22</sup> Especially, additional studies have also indicated that MMF was more effective and triggered less AEs than AZA.<sup>25 26</sup> In patients experiencing AEs or poor response to AZA, MMF is recommended as an alternative therapy.<sup>16</sup>

Although MMF is increasingly employed in NMOSD, there is still controversy about its related harms and benefits. At present, there are mainly two published articles that are relevant to the topic and purpose of our research.<sup>27 28</sup> Nevertheless, these two studies have some imperfections in the direct evaluation of the efficacy and safety of MMF in the treatment of NMOSD patients. For example, the Espiritu and Pasco paper did not quantitatively evaluate the efficacy of MMF in the treatment of NMOSD and did not

compare the AEs of MMF with other drugs in the treatment of NMOSD. Additionally, Huang et al. 's research was a network meta-analysis and the literature related to MMF in this paper was three observational studies that made the number of included studies and closed loops per comparison were few, which might lower the reliability of the findings. In our study, the database we searched includes not only the English database but also the Chinese database. The retrieval time is limited to June 2020, and we will add 3 retrospective studies involving 471 patients with NMOSD,<sup>29-31</sup> which makes the retrieval literature more comprehensive. At the same time, the conclusions of the previously published literature about the clinical effect of MMF were inconsistent. Poupart argued that RTX was clinically better tolerated than MMF.<sup>30</sup> But Huang et al argued that MMF had the best drug tolerance and was superior to RTX.<sup>31</sup> We expect our research to help solve this problem as well.

#### 2. Methods

 This protocol has been registered on PROSPERO (registration number: CRD 42020164179). Our protocol will follow the Meta-analysis of Observational Studies in Epidemiology (MOOSE),<sup>32</sup> the Cochrane Handbook for Systematic Reviews of Interventions and the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocol (PRISMA-P) statement guidelines. <sup>33 34</sup>

#### 2.1 Inclusion criteria for study selection

#### 2.1.1 Types of studies

All comparative researches, from randomized controlled trials (RCTs) to cohort studies, and case-control study, covering at least two interventions, will be included. The current clinical trial results will be objectively integrated, which is conducive to the evaluation of the efficacy and safety of MMF for NMOSD. We will exclude reviews, qualitative studies, animal trials, laboratory studies and studies only involving one intervention.

#### 2.1.2 Types of patients

Patients diagnosed as having NMOSD will be included in this study.<sup>5 35</sup> There will be no restrictions based on other conditions, such as age at onset, sex, ethnicity, educational or economic status, number of pre-treatment relapses, previous treatment, duration of illness, disease severity, and baseline expanded disability status scales (EDSS), AQP4-IgG serological status.

#### 2.1.3 Types of interventions

Trials comparing MMF to placebo or any other active substances, including AZA, cyclophosphamide, methotrexate, mitoxantrone, tacrolimus, cyclosporine, and monoclonal antibodies, will be considered. Besides, the types, dosage, and frequency of MMF were not limited. Studies that MMF with combination therapy fail to objectively evaluate the efficacy and safety of MMF will be eliminated.

#### 2.1.4 Types of outcome measures

#### 2.1.4.1 Primary outcomes

- (1) EDSS: Disability progression was characterized as an increase in the Kurtzke EDSS by at least 1 point above the pre-treatment score if baseline score < 5.5, and by at least half-point if baseline score > 5.5. Outcome measured was the mean changes of EDSS before and after MMF treatment.<sup>36 37</sup>
- (2) Annualized relapse rate (ARR): Relapse is equivalent to a neurologic symptom lasting for > 24 h, which occurs at least 30 days after the onset of a preceding event. ARR is computed as the number of relapses divided by the time in years (days). Post-treatment ARR was contrasted with pre-treatment ARR. <sup>38</sup>

#### 2.1.4.2 Secondary outcomes

- The frequency and extent of AEs: During treatment and follow-up periods, any symptomatic events which had a possible, probable or definite causal relationship to MMF treatment were defined as AEs.
- (2) Relapse-free rate: The absence of relapse during the observation period of the study reported as percentage per study.<sup>35</sup>
- (3) Best-corrected visual acuity (BCVA): BCVA was measured using a standardized test, such as the ETDRS chart, Snellen chart or similar method, and other visual acuity measures would be allowed if findings could be justified as well as validated concerning accepted relevant standard measures. Outcome measured was the mean change of BCVA from before and after MMF treatment.<sup>39</sup>
- (4) Time to the next attack.

#### 2.1.4.3 Security index

The safety was assessed by the occurrence of AEs. Any unexpected events that occurred during the studies will be recorded on an AEs report form, including: <sup>28</sup>

- (1) General physical examination (temperature, pulse, respiration, blood pressure).
- (2) Routine examination of blood, urine and stool.
- (3) Liver and kidney function examination.
- (4) Gastrointestinal discomfort.
- (5) Hair loss or Alopecia.

- (6) Allergic or Anaphylactoid reactions.
- (7) Drug discontinued due to drug-related AEs.
- (8) Possible AEs and related detection indicators.

#### 2.2 Search methods for the identification of studies

#### 2.2.1 Electronic searches

A relevant literature search by sensitive search strategies was conducted using the following electronic databases from their inception to June 31, 2020: PubMed, Web of Science, EMBASE, the Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang Database, China Science and Technology Journal database (VIP) and Chinese Biomedical Literature database (CBM). Search methods of MeSH terms with free words were applied in English databases. The related terms are as follows: Participants (neuromyelitis optica, neuromyelitis optica spectrum disorders, Devic Neuromyelitis Optica, Devic's Neuromyelitis Optica, Devic's Syndrome, NMO spectrum disorders), Intervention (mycophenolic acid, mycophenolate mofetil, "mofetil, mycophenolate", cellcept, myfortic, RS61443). The search strategy for PubMed is described in Table 1, which will include all search terms, and other searches will be carried out based on those results. This will be suitably adapted to search in the other databases. There are no limits on language and publication status.

#### 2.2.2 Searching other resources

we will also search PROSPERO, the International Clinical Trials Registry Platform (ICTRP), ClinicalTrials.gov, dissertations, and gray literature to identify systematic reviews or clinical trials related to mycophenolate mofetil and neuromyelitis optica spectrum disorders. Manual searches will be conducted for related journals and

#### **BMJ** Open

conference processes. We will also review papers and bibliographies included in the trials.

2.3 Data collection and analysis

#### 2.3.1 Selection of studies

Two reviewers (MYH and ZQL) will independently browse the titles and abstracts of all of the retrieved records to distinguish and exclude any irrelevant articles. Studies only related to human subjects are to be included. Any discord will be resolved by discussion between the two authors and an arbiter (MJ). The selection procedure for the study is shown in a PRISMA flow chart (Fig. 1).

#### 2.3.2 Data extraction and management

Based on the inclusion criteria, a standard form of data collection will be produced prior to data extraction. Search results will be entered into an EndNote X9 database and duplicate entries removed. Two authors (MYH and ZQL) will extract the data of interest from the eligible study and enter the data extraction sheet as follows: The basic characteristics of each study (study design or methods, author, title, source/journal, time of publication, country, hospital setting); participants characteristics (average age, gender, sample size, inclusion and exclusion criteria, baseline situation); Interventions (type, duration, frequency and dosage of MMF, randomization, allocation concealment, blinding methods); Comparators (AZA, tacrolimus, cyclosporine, monoclonal antibodies, and placebo, etc); Outcomes (measures, main outcomes, security indexes, and follow up); If funded, it will also be recorded. When the consensus on data extraction is not available through discussion, the third reviewer (MJ) will make a decision.

#### 2.3.3 Assessment of risk of bias

Two authors (Yang Chen and LQN) will independently estimate the risk and bias using the Cochrane risk of bias (ROB) assessment tool for RCTs.<sup>40</sup> Methodological quality evaluation of the included observational studies will be carried out using the Newcastle–Ottawa Scale (NOS).<sup>41</sup> The RevMan software program (V.5.3) will document the selected details of each study.<sup>42</sup>

#### 2.3.4 Measures of treatment effect

The risk ratio (RR) and 95% confidence interval (CI) will be used to analyze dichotomous data and calculate the treatment effect. A weighted mean difference (WMD) or a standard mean difference (SMD) with 95% CIs will be used to analyze continuous outcomes.

#### 2.3.5 Unit of analysis issue

 We will only extract the 1st experimental period data of crossover trials to avoid carryover effects. In the meantime, given that there are multiple intervention groups in trials, we will combine all analogous groups into a single pairwise comparison to avoid a unit of analysis issue.

#### 2.3.6 Management of missing data

Reviewer (YLQ and You Chen) will contact the appropriate author of the included trials for clarification or more details via email and telephone if necessary. The missing data will be deleted, if there is no response from the author. That will be addressed in the discussion in this case. If quantitative data were not available, then the qualitative analysis should be used.

#### 2.3.7 Assessment of heterogeneity and data synthesis

We will use all of the case data for the analysis data. Heterogeneity will be tested with a standard Chisquare test.<sup>43</sup> To quantify the impact of the statistical heterogeneity on the systematic review, the I<sup>2</sup> value will be applied to calculate and present the heterogeneity degree. If P>0.1, I<sup>2</sup><50%, it is considered that there is no heterogeneity between the trials, and the model of fixed effect will be used, otherwise, the model of random effect will be adopted. All statistical analyzes will be performed using the RevMan5.3 software provided by the Cochrane Collaboration. Using the software to obtain forest plots and test the heterogeneity between the included studies. The Grades of Recommendation, Assessment, Development and Evaluation (GRADE) will be used to assess the meta-analysis findings and determine the quality of evidence. Where meta-analysis may not be not feasible due to lack of clinical trials or heterogeneity, systematic narrative synthesis will be adopted.

#### 2.3.8 Assessment of reporting biases

When 10 or more studies are included in a meta-analysis, we will evaluate funnel plot

asymmetry for reporting biases and small-study effects using Egger's method.<sup>44</sup> For Egger's test, P value of greater than 0.05 was determined as no significant publishing bias or small-study effects in studies. As funnel plot asymmetry does not necessarily suggest reporting bias, we will attempt to recognize potential causes for the asymmetry, including poor methodological quality and true heterogeneity of studies.

# 2.3.9 Subgroup analysis

Upon detection of heterogeneity, a subgroup analysis will be carried out to judge the source of heterogeneity. The criteria for a subgroup analysis are as follows:

- (1) Age.
- (2) Type of MMF.
- (3) Research type.
- (4) Participation population.
- (5) Type of control interventions.
- (6) Intervention dosage, frequency and duration.
- (7) AQP4-IgG serological status.

#### 2.3.10 Sensitivity analysis

The ROB tool will be used to estimate methodological quality in the case of sufficient data from trials. Sensitivity analysis will be performed to determine the robustness of aggregate estimates and to detect whether any single study accounts for a substantial proportion of heterogeneity by eliminating the included studies from the summary review one by one. If low-quality articles are deleted, then a second meta-analysis will be carried out. Comparison and discussion of the results and effect size of the two meta-analyses will be held. <sup>45</sup>

**2.4 Patient and public involvement** Patients and/or the public will not participate in the study. However, once scientific publications disseminate our findings, they are circulated across social networks so that our conclusions will affect the actions of neuro-ophthalmologists and health policymakers.

**2.5 Ethics and dissemination** Because the data used for this systematic review will be exclusively extracted from published studies, ethical approval and informed consent of patients will not be required. The systematic review will be published in a peer-

reviewed journal, presented at conferences and will be shared on social media platforms.

#### Discussion

Pathogenesis, diagnosis and treatment of NMO are rapidly growing areas of research as AQP4-IgG were first identified. Patients with NMOSD should receive standardized and personalized immunotherapy as soon as possible, as any further acute episodes may result in severe and often irreversible disability. The challenges in discovering new and better drugs for NMO are the rareness of the disease and the unfavorable prognosis in many cases, which make clinical studies with placebo groups difficult.<sup>16</sup> Many studies have confirmed the efficacy and promising prospect of MMF in the treatment of NMOSD,<sup>21-24</sup> and only a few AEs were reported. <sup>21 22</sup> Additional studies have also indicated that MMF was more effective and triggered less AEs than AZA.<sup>25 26</sup> However, its therapeutic effect and safety remain controversial. Although there has been two published literature that is relevant to the topic of this study,<sup>27 28</sup> both of them have certain defects, and they can only provide answers about the efficacy or safety of MMF in the treatment of NMOSD from partial perspectives or conclusions. If our paper is completed, it will be a currently searchable protocol for a traditional meta-and systematic review that directly and synthetically evaluates the efficacy and safety of MMF in the treatment of NMOSD. One of the strengths of this protocol will use a comprehensive search strategy of published literature. The overall data used in each analysis will be evaluated qualitatively and quantitatively. The sources of heterogeneity and different subgroups of the articles will be analyzed to comprehensively evaluate the efficacy and safety of MMF in the treatment of NMOSD, and to increase the credibility of the article content and conclusions. We expect that this systematic review will benefit patients with NMOSD, physicians, health care administrators and policymakers.

#### Author contributions

MYH conceived and designed the protocol, and MYH drafted the protocol manuscript. MYH developed the search strategy, with input from ZQL and LQN. MYH and ZQL

#### **BMJ** Open

planned data extraction. MYH, Yang Chen and ZJW planned the quality appraisal of
all included studies. MYH, ZQL, LQN, Yang Chen, HM, You Chen, ZJW, YLQ and
MJ critically revised the manuscript for methodological and intellectual content. All
authors approved the final version.
Conceptualization: Meng-Yu Han, Zi-Qiang Liu, Zhi-Jun Wang, Ming Jin.
Data curation: Meng-Yu Han, Zi-Qiang Liu, Lu-Qi Nong, Huan Meng.
Formal analysis: Meng-Yu Han, Zi-Qiang Liu.
Funding acquisition: Meng-Yu Han.
Investigation: Ming Jin.
Methodology: Meng-Yu Han, Zi-Qiang Liu, Lu-Qi Nong, You Chen.
Project administration: Ming Jin.
Resources: Meng-Yu Han, Zi-Qiang Liu, Lu-Qi Nong, Ming Jin.
Software: Meng-Yu Han, Zi-Qiang Liu, Lu-Qi Nong.
Supervision: Meng-Yu Han, Zhi-Jun Wang, Ming Jin.
Validation: Huan Meng, Yang Chen, Ya-li Qin, Ming Jin.
Visualization: Huan Meng, Yang Chen, Ya-li Qin, Ming Jin.
Writing – original draft: Meng-Yu Han, Zi-Qiang Liu, Lu-Qi Nong, Ming Jin.
Writing – review & editing: Meng-Yu Han, Zi-Qiang Liu, Lu-Qi Nong, Ming Jin.

**Funding:** This study was funded by the National Natural Science Foundation of China (No. 81574029). The funders had no role in the design, execution, or writing of the study.

Competing interests: None declared.

#### Reference

[1] Jasiak-Zatonska M, Kalinowska-Lyszczarz A, Michalak S, & Kozubski W. The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives. International J Molecular Sciences 2016;17(3):273. [2] Jarius S, Wildemann B. On the contribution of Thomas Clifford Allbutt, F.R.S., to the early history of neuromyelitis optica. J Neurol 2013; 260:100-104.

[3] Yang X, Ransom R, Ma J F. The role of AQP4 in neuromyelitis optica: more answers, more questions. Neuroimmunol 2016;298:63-70.

[4] Wingerchuk D M, Lennon V A, Lucchinetti C F, et al. The spectrum of neuromyelitis optica. The Lancet Neurology 2007;6(9):805-815.

[5] Wingerchuk D M, Banwell B, Bennett J L, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85(2):177-189.

[6] Pandit L, Asgari N, Apiwattanakul M, et al. Demographic and clinical features of neuromyelitis optica: A review. Mult Scler 2015;21(7):845-853.

[7] Bukhari W, Prain KM, Waters P, et al. Incidence and Prevalence of NMOSD in Australia and New Zealand. J Neurol Neurosurg Psychiatry 2017;88(8): 632-638.
[8] Viswanathan S, WallL M. A nationwide epidemiological study on the prevalence of multiple sclerosis and neuromyelitis optica spectrum disorder with important multi-ethnic differences in Malaysia. Muh Scler 2019;25(11): 1452-1461.

[9] Miyamoto K, Fujihara K, Kira J1, eta1. Nationwide epidemiological study of neuromyelitis optician Japan. J Neurol Neurosurg Psychiatry 2018;89(6): 667-668.

[10] Wingerchuk D M, Hogancamp W F, O'Brien P C, et al. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53,1107.

[11] Jiao Y, Fryer JP, Lennon VA, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology 2013;81:1197-1204.

[12] Drori T, ChapmanJ. Diagnosis and classification of neuromyelitis optica (Devic's syndrome). Autoimmun Rev 2014;13(4-5):531–533.

[13] Optic Neuritis Study Group. Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial. Ophthalmology 2008;115(6): 1079-1082.

[14] Papadopoulos MC, Bennett JI, Verkman AS. Treatment of neuromyelitis optica state-of-the-art and emerging therapies. Nat Rev Neurol 2014;10(9):493-506.

[15] Wu Y, Zhong L, Geng J.Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models. Mult Scler Relat disord 2019;27(1):412-418.

#### **BMJ** Open

[16] Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 2014; 261(1):1-16.

[17] Elsone L, Kitley J, Luppe S, et al. Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK
[J]. Mult Scler 2014;20(11):1533-1540.

[18] Torres J, Pruitt A, Balcer L, et al. Analysis of the treatment of neuromyelitis optica.J Neurol Sci 2015;351(1-2):31-35.

[19] Annovazzi P, Capobianco M, Moiola L, et al. Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study. J Neurol 2016; 263(9): 1727-1735.

[20] Collongues, N, de Seze, J. An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica. Ther Adv Neurol Disord 2016;9(3):180-188.

[21] Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 2009; 66(9):1128-33.

[22] Huh S Y, Kim S H, Hyun J W, et al. Mycophenolate Mofetil in the Treatment of Neuromyelitis Optica Spectrum Disorder. JAMA Neurology 2014;71(11):1372-1378.

[23] Chen H, Zhang Y, Shi Z, et al. The Efficacy and Tolerability of Mycophenolate Mofetil in Treating Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder in Western China. Clin Neuropharmacol 2016; 39(2):81-87.

[24] Jiao Y, Cui L, Zhang W, et al. Dose effects of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorders: a case series study. BMC Neurology 2018;18(1):47.

[25] Chen H, Qiu W, Zhang Q, et al. Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder. Eur J Neurol 2017;24(1):219-226.

[26] Yang Y, Wang C J, Wang B J, et al. Comparison of efficacy and tolerability of

azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder. J Neurol Sci 2018;385:192-197.

 [27] Huang W, Wang L, Zhang B, Zhou L, Zhang T, Quan C. Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis optica spectrum disorders: A systematic review and network metaanalysis. Mult Scler Relat Disord 2019;35:246-252.

[28] Espiritu AI, Pasco PMD. Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: A systematic review and meta-analysis. Mult Scler Relat Disord 2019;33(8):22-32.

[29] Zhou Y, Zhong X, Shu Y, et al. Clinical course, treatment responses and outcomes in Chinese paediatric neuromyelitis optica spectrum disorder. Mult Scler Relat Disord 2019;28:213-220.

[30] Poupart J, Giovannelli J, Deschamps R, et al. Evaluation of efficacy and tolerability of first-line therapies in NMOSD. Neurology 2020;94(15):e1645-e1656..

[31] Shi Z, Du Q, Chen H, et al. Effects of immunotherapies and prognostic predictors in neuromyelitis optica spectrum disorder: a prospective cohort study. J Neurol 2020; 267(4):913-924.

[32] Stroup DF, Berlin JA, Morton SC, et al, Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 283(15);2008-2012.

[33] Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;350:7647.

[34] Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.

[35] Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66 (10), 1485-1489.

[36] Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurol Int 1983;33 (11):1444-1452.

[37] Enriquez C A G, Espiritu A I, Pasco P M D. Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: A systematic review. Journal

1 2					
3 4	of Neuroimn	nunology 2019;332(7):126-134.			
5 6	[38] Lavery	AM, Verhey LH, Waldman AT. Outcome measures in relapsing-remitting			
7 8	multiple sclerosis: capturing disability and disease progression in clinical trials. Mult				
9 10	Scler Int 201	4;2014, 262350.			
11 12	[39] Squires H, Poku E, Bermejo I, et al. A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults. Health Technol Assess 2017;21(68):1-170.				
13 14					
15 16					
17 18	[40] Savović	J, Weeks L, Sterne JA, et al. Evaluation of the Cochrane Collaboration's			
19 20	tool for asse	ssing the risk of bias in randomized trials: focus groups, online survey,			
20 21 22	proposed rec	ommendations and their implementation. Syst Rev 2014;15:37.			
23	[41] Wells (	G, Shea B, O'Connell D, et al. The Newcastle–Ottawa scale (NOS) for			
24 25	assessing the	quality of nonrandomised studies in meta-analyses. Mult Scler 13(8); 968-			
26 27	974.				
28 29	[42] Collabo	[42] Collaboration RTC. Review Manager (RevMan). 5.0. COPENHAGEN: THE			
30 31	NORDIC COCHRANE COLLABORATION,2008.				
32 33	[43] Chen E	B, Benedetti A. Quantifying heterogeneity in individual participant data			
34 35	meta-analysi	s with binary outcomes. Syst Rev 2017;6:243.			
36 37	[44] Egger M, Smith GD, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.				
38 39					
40 41	[45] Shih KC, Lun CN, Jhanji V, et al. Systematic review of randomized con				
42 43	trials in the t	reatment of dry eye disease in Sjogren syndrome. J Inflamm (LOND) 2017;			
44 45	14:26.				
46 47					
48 49	Table 1 Sear	ch strategy used in PubMed database.			
50 51	Number	Search terms			
52 53	#1	("Neuromyelitis Optica"[Mesh]) OR (((((neuromyelitis optica			
54 55		spectrum disorders [Title/Abstract]) OR Devic Neuromyelitis Optica			
56 57		[Title/Abstract]) OR Devic's Neuromyelitis Optica [Title/Abstract])			
57 58 59		OR Devic's Syndrome [Title/Abstract]) OR NMO spectrum disorders			
60					

	[Title/Abstract])							
#2	("Mycophenolic Acid"[Mesh]) OR (((((Mycophenolate Mofetil							
	[Title/Abstract]) OR "Mofetil, Mycophenolate" [Title/Abstract]) Ol							
	Cellcept [Title/Abstract]) OR Myfortic [Title/Abstract]) OR RS61443							
	[Title/Abstract])							
#3	#1 and #2							

Figure 1. The PRISMA flow chart of the selection process.

or beer teriew only




Figure1. The PRISMA flow chart of the selection process.

BMJ Open: first published as 10.1136/bmjopen-2020-040371 on 30 November 2020. Downloaded from http://bmjopen.bmj.com/ on April 23, 2024 by guest. Protected by copyright

# Reporting checklist for protocol of a systematic review.

Based on the PRISMA-P guidelines.

# Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMA-Preporting guidelines, and cite them as:

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.

-			Page
		Reporting Item	Number
Title			
Identification	<u>#1a</u>	Identify the report as a protocol of a systematic review	Page 1
Update	<u>#1b</u>	If the protocol is for an update of a previous systematic	
		review, identify as such	
	For pe	eer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2 3	Registration			
4 5		<u>#2</u>	If registered, provide the name of the registry (such as	Page 2
6 7 8			PROSPERO) and registration number	
9 10 11 12	Authors			
13 14	Contact	<u>#3a</u>	Provide name, institutional affiliation, e-mail address of all	Page 1
15 16			protocol authors; provide physical mailing address of	
17 18 19			corresponding author	
20 21	Contribution	<u>#3b</u>	Describe contributions of protocol authors and identify the	Page1,11,12
22 23			guarantor of the review	
24 25 26 27	Amendments			
28 29 30 31 32 33 34 35 36		<u>#4</u>	If the protocol represents an amendment of a previously	
			completed or published protocol, identify as such and list	
			changes; otherwise, state plan for documenting important	
			protocol amendments	
37 38				
39 40 41	Support			
41 42 43 44	Sources	<u>#5a</u>	Indicate sources of financial or other support for the review	Page 12
45 46 47	Sponsor	<u>#5b</u>	Provide name for the review funder and / or sponsor	Page 12
48 49 50 51 52 53 54 55	Role of sponsor or	<u>#5c</u>	Describe roles of funder(s), sponsor(s), and / or	Page 12
	funder		institution(s), if any, in developing the protocol	
	Introduction			
56 57 58	Rationale	<u>#6</u>	Describe the rationale for the review in the context of what	Page 2,3,4,5
59 60		For pee	er review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2			is already known	
- 3 4	Objectives	<u>#7</u>	Provide an explicit statement of the question(s) the review	Page 5,6,7
5 6 7			will address with reference to participants, interventions,	
7 8 9			comparators, and outcomes (PICO)	
9 10 11 12 13 14 15	Methods			
	Eligibility criteria	<u>#8</u>	Specify the study characteristics (such as PICO, study	Page 7,8
16 17			design, setting, time frame) and report characteristics	
18 19 20			(such as years considered, language, publication status) to	
20 21 22			be used as criteria for eligibility for the review	
23 24 25 26	Information	#9	Describe all intended information sources (such as	Page 7,8
	sources	<u></u>	electronic databases, contact with study authors, trial	
27 28 29	ocuroco		registers or other grey literature sources) with planned	
30 31 32 33 34 35 36 37 38 39 40			dates of coverage	
	Search strategy	<u>#10</u>	Present draft of search strategy to be used for at least one	Page 7
			electronic database, including planned limits, such that it	
			could be repeated	
41 42 43	Study records -	<u>#11a</u>	Describe the mechanism(s) that will be used to manage	Page 8
44 45	data management		records and data throughout the review	
46 47 48	Study records -	<u>#11b</u>	State the process that will be used for selecting studies	Page 8
49 50	selection process		(such as two independent reviewers) through each phase	
51 52 53 54 55			of the review (that is, screening, eligibility and inclusion in	
			meta-analysis)	
56 57	Study records -	<u>#11c</u>	Describe planned method of extracting data from reports	Page 8,9
58 59 60		For pee	er review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

Page 23 of 23

# BMJ Open

1	data collection		(such as piloting forms, done independently, in duplicate),	
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43	process		any processes for obtaining and confirming data from	
			investigators	
	Data items	<u>#12</u>	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	Page 8
	Outcomes and prioritization	<u>#13</u>	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	Page 6,7
	Risk of bias in	<u>#14</u>	Describe anticipated methods for assessing risk of bias of	Page 8
	individual studies		individual studies, including whether this will be done at	
			the outcome or study level, or both; state how this	
			information will be used in data synthesis	
	Data synthesis	<u>#15a</u>	Describe criteria under which study data will be quantitatively synthesised	Page 9
	Data synthesis	<u>#15b</u>	If data are appropriate for quantitative synthesis, describe	Page 9
			planned summary measures, methods of handling data	-
			and methods of combining data from studies, including any	
44 45 46			planned exploration of consistency (such as I2, Kendall's	
40 47 48			т)	
49 50				
51 52	Data synthesis	<u>#15c</u>	Describe any proposed additional analyses (such as	Page 9,10
53 54 55			sensitivity or subgroup analyses, meta-regression)	
55 56 57 58	Data synthesis	<u>#15d</u>	If quantitative synthesis is not appropriate, describe the	Page 9
59 60		For pe	er review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2			type of summary planned	
3 4 5 6 7 8	Meta-bias(es)	<u>#16</u>	Specify any planned assessment of meta-bias(es) (such	Page 8,9,10
			as publication bias across studies, selective reporting	
			within studies)	
7	License CC-BY 4.0	. This c		
54 55 56				
57 58				
59 60		For pee	er review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	